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Ampicillin sodium and ampicillin trihydrate were given to llamas by 
intramuscular(IM) administration at a dose of 12 mg/kg. The first order absorption 
rate constant(Ka ) for sodium ampicillin was 69.45±47.34 If', while the first order 
elimination rate constant(Kei) was 0.86±0.28  yielding an elimination half-life(ti/2) 
of 0.81±0.31 h. The mean peak ampicillin plasma concentration(Cmax) was 
14.82±5.96 .tg /ml at 0.13±0.12 h.  The C. of ampicillin trihydrate at a dose of 
12 mg/kg following IM administration in llamas was less than 0.1 µg/ml. The low 
ampicillin plasma concentrations after the IM administration of ampicillin trihydrate 
is probably due to slow drug absorption as ampicillin trihydrate is much less soluble 
than ampicillin sodium. 
Gentamicin was administered by a once daily IV bolus injection to llamas for 
four days. The pharmacokinetic parameters, half-lives, the area under the curve, 
body clearance, and the apparent volume of distribution from the four doses were 
not statistically significantly different( p-value > 0.05).  The t1 /20, CL, and Vass 
were 2.27±0.13 h, 0.12±0.02 1/h/kg, and 0.39±0.08 1/kg respectively. 
Redacted for PrivacyAmikacin was given as an IM injection to llamas at a dose of 12 mg/kg. The 
absorption rate constant(Ka ) was 3.75±0.15 If'. The elimination rate constant(Kei ) 
was 0.27±0.01 114, whereas the elimination rate constant after a single IV bolus 
administration of amikacin at the same dose was 0.25±0.01 111. No statistically 
significant differences(p > 0.05) were observed for any of the pharmacokinetic 
parameters between IM and IV administrations. The half-lives of amikacin were 
2.77±0.18 h(IV) and 2.60±0.14 h(IM). The clearances  were 0.08± 0.01(IV) and 
0.09±0.01(IM)1/h/kg. The apparent volumes of distribution were 0.33±0.04 1/kg(IV) 
and 0.34±0.04(A4) 1/kg. 
Omeprazole was given IM injection at a dose of 0.8 mg/kg. The 
pharmacokinetic parameters obtained had the following values, Ka of 100±0.00 
IQ of 0.68±0.04 11-1, half-life of 1.02±0.07 h, Vd of 1.54±0.10 1/kg, CL of 
1.05±0.13 1 /kg/h, calculated C. of 500.54±31.14 ng/ml, calculated t. of 
0.05±0.0 h,  observed C. of 567.39±109.76 ng/ml, and observed t. of 
0.083±0.0 h. Rectal administration of the same omeprazole formulation as the IM 
administration showed little omeprazole absorption with plasma concentrations of 
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 PHARMACOKINETICS OF AMPICILLIN, GENTAMICIN, AMIKACIN
 
AND OMEPRAZOLE IN LLAMAS
 
CHAPTER 1 
INTRODUCTION 
Common problems in llamas are bacterial infections of the reproductive, 
gastrointestinal, and respiratory systems. The pathologic changes are frequently 
severe before the clinical changes are observed. Therefore, the appropriate antibiotic 
selection and the dosage regimen are very important. The utility of pharmacokinetics 
in clinical pharmacology rests largely on the premise that the therapeutic range of 
plasma concentrations can be defined for a drug. In llamas, pharmacokinetic studies 
of a few antimicrobial agents have been reported. This research aimed to determine 
in llamas the pharmacokinetics of three antibiotics. First, two forms of ampicillin, 
the sodium salt and trihydrate form given by intramuscular injection at a dose of 12 
mg/kg body weight. The dose was based on a previous study of ampicillin sodium 
given intravenously in llamas. The objectives for the ampicillin studies were to 
determine if ampicillin given intramuscularly can provide adequate therapy and to 
investigate if llamas can absorb the ampicillin from the injection site when the 
trihydrate form is given. Second, gentamicin given by bolus intravenous injection 
at a daily dose of 4 mg/kg body weight for four days. The dose was based on a 
previous study of tobramycin given intravenously in llamas. The objective for 
gentamicin study was to determine that repeated gentamicin dosing of 4 mg/kg 
body weight can provide appropriate peak and trough plasma concentrations. 
Third, amikacin given by intravenous and intramuscular injections. The amikacin 
dose was also based on a previous study of tobramycin in llamas. The objective for 2 
the amikacin study was to determine the pharmacokinetics from intravenous and 
intramuscular injections. 
Gastric ulcer or perforating ulcer in the third compartment of llamas has 
been an important problem in llamas because of high acid secretion. H2-receptor 
antagonists have been ineffective in treatment in llamas. Omeprazole given 
intravenously was an effective antiulcer agent but, it is commercially available only 
in an oral form of a capsule containing enteric coated granules. Since the 
omeprazole is inactivated after oral administration in llamas, alternative routes, 
intramuscular and rectal administrations were performed in this research at a dose 
of 0.8 mg/kg body weight. 
In each study, six sexually mature healthy llamas were used. Drug plasma 
samples were taken at any times required after the drug administrations and were 
kept at -20° C until assayed. All drug plasma concentrations were assayed by using 
a reversed phase chromatography with a C-18 column and a UV-detector. 
Pharmacokinetic analysis was performed by using RSTRIP computer software. The 
drug plasma concentrations as a function of times after administration of each llama 
were fiited to a polyexponetial equation with non-linear least squares. Then, 
pharmacokinetic parameters and dosage regimens were calculated from the best fits. 3 
CHAPTER 2
 
PHARMACOKINETICS OF AMPICILLIN GIVEN IM ADMINISTRATION 
IN LLAMAS 
2.1. ABSTRACT 
Ampicillin sodium and ampicillin trihydrate were given by IM injection to 
six llamas. The pharmacokinetics of ampicillin sodium following single IM 
administration at 12 mg/kg body weight yielded a first order absorption rate 
constant (Ka ) of 69.45 ± 47.34 If' and first order elimination (Kel) of 0.86 ± 
0.28  The harmonic mean elimination half-life (t112) was 0.81 ± 0.31 h, with the 
mean peak plasma concentration (Cmax) being 14.82 ± 5.96 µg/m1 at 0.13 ± 0.12 h. 
The apparent volume of distribution was 0.78 ± 0.191/kg and the total body 
clearance was 0.58 ± 0.271/kg/h. The Cmax of ampicillin trihydrate at a dose of 12 
mg/kg after IM administration in llamas was less than 0.1 µg/ml. The low absorption 
of ampicillin after IM injection of ampicillin trihydrate suspension appears to be low 
due to the low solubility of this form of the drug. The dosing regimen for IM 
injection of 24 mg/kg every 12 hours or 12 mg/kg every 6 hours is higher than what 
is recommended for IV (12 mg/kg every 12 hours). 
2.2. INTRODUCTION 
Both gram-negative and gram-positive bacterial infections are common 
problems in the llamas (Thedford and Johnson, 1989; Fowler, 1989; Smith, 1993). 4 
While vaccination programs have effectively decreased the incidence of clostridial 
infection; mixed bacterial respiratory, gastrointestinal and reproductive infections 
are frequently encountered (Thedford and Johnson, 1989). Respiratory and 
uterine infections are of particular concern since, in llamas, pathologic changes may 
be extensive prior to the time that overt clinical changes are observed. Bacterial 
diseases having been reported by veterinarians as occuring in llamas and alpacas are 
shown in table 2.1 (Thedford and Johnson, 1989). Therapy of an infectious disease 
in the llama depends upon the microorganism involved. 
The penicillin family of antibiotics remains an important part of the 
antimicrobial armamentarium. In general, these agents have bactericidal activity, 
excellent distribution throughout the body, low toxicity, and efficacy against 
infections caused by susceptible bacteria. The initial introduction of aqueous 
penicillin G for treatment of streptococcal and staphylococcal infections was an 
important pharmacologic landmark. The basic structure of penicillin 
(6-aminopenicillanic acid) consists of a thiazolidine ring, an attached beta-lactam 
ring, and a side chain (figure2.1). Manipulations of the side chain have altered the 
antibacterial spectrum, beta-lactamase intolerance, and pharmacokinetic properties. 
Subsequently, the aminopenicillins (such as ampicillin and amoxicillin) were 
developed because of the need for gram-negative antimicrobial activity. Their 
spectra include Escherichia colt, Proteus mirabilis, Shigella, Salmonella, Listeria, 
Haemophilus, and Neisseria. The search for a penicillin with additional 
antimicrobial activity against the Enterobacteriaceae and Pseudomonas aeruginosa 
led to the development of the carboxypenicillins (carbenicillin, ticarcillin, and 
temocillin) and the ureidopenicillins (mezlocillin, azlocillin, piperacillin, and 5 
apalcillin). The emergence of penicillinase-producing Staphylococcus aureus 
prompted the development of the penicillinase-resistant penicillins (for example, 
methicillin, oxacillin, and nafcillin), in which an acyl side chain prevented disruption 
of the beta-lactamase ring. Bacterial beta-lactamase may hydrolytically attack the 
beta-lactam ring and render the penicillin inactive. This process can be prevented 
by adding certain acyl side chains that sterically protect the beta-lactam ring or by 
combining the penicillin with a beta-lactamase inhibitor. 
Finally, the combination of a beta-lactamase inhibitor (clavulanic acid or 
sulbactam) and an aminopenicillin or ticarcillin has further extended their 
antibacterial spectra. The development of an ideal penicillin that is rapidly 
bactericidal, nonsensitizing, nontoxic, bioavailable, resistant to beta-lactamase, and 
without inoculum effect and that has a high affinity for penicillin-binding proteins 
remains the goal (Wright, 1991). 
Penicillins inhibit the synthesis of the bacterial cell wall and activation of the 
endogenous autolytic system (Tomasz, 1979). The action of penicillins necessitates 
the presence of a cell wall that contains peptidoglycans. In actively dividing bacteria, 
the penicillins inhibit the enzymes (transpeptidase, carboxypeptidase, and 
endopeptidase) that create the cross-linkage between the peptide chain and thereby 
prevent the development of the normal peptidoglycan structure. The ability to 
penetrate the cell wall and the degree of affinity to these penicillin-binding proteins 
determine the activity of the penicillin on the bacterium. Penicillins have been found 
to activate the endogenous autolytic system of bacteria, which initiates cell lysis and 
death (Tomasz, 1979). 6 
Penicillins are not metabolized or only minimally metabolized. All but a few 
are primarily excreted by the kidneys via both glomerular filtration and active tubular 
secretion. Ampicillin appears in the bile, undergoes enterohepatic circulation, and is 
excreted in feces (Sande & Mandell, 1980). 
Ampicillin is an aminopenicillin, the first group of penicillins having activity 
against gram-negative bacteria. Ampicillin was formulated by the addition of an 
amino group to the basic benzylpenicillin molecule (figure 2.1). Ampicillin was 
found to have more activity than penicillin G against enterococci and Haemophilus 
influenzae but somewhat less activity against S. pyogenes, pneumococci, Neisseria, 
and Clostridium species. Ampicillin, also, initially had activity against many gram-
negative bacteria including Escherichia coli, Proteus mirabilis, Salmonella, 
Shigella, and beta-lactamase-negative H. influenzae. Ampicillin has little 
or no activity against Klebsiella, Serratia, Enterobacter, and P. aeruginosa. More 
recently, because of increasing bacterial resistance, ampicillin has been shown to 
have less activity against some strains of E. coli, Salmonella, Shigella, and 
N. gonorrhoeae. Because of the low cost and safe profile of toxicity of ampicillin, 
it can be used for treatment of some of these infections if the susceptibility tests 
have shown the infecting bacterial strain is sensitive. Because ampicillin is more 
stable in gastric acid and absorption is unaffected by food, it is suitable for oral use. 
After oral administration of 0.5 g of ampicillin in the human, peak serum levels are 
noted in approximately 2 hours but seldom exceed 4 tg/m1; thus, it is limited to 
treatment of mild infections. For serious infections, ampicillin should be 
administered intravenously. Only approximately 15 to 25% of ampicillin is protein 
bound and is rapidly excreted through the kidneys (Wright, 1991). 7 
Table 2.1 Bacterial diseases have been reported in llamas and alpacas(Thedford and 
Johnson, 1989). 
Disease  Bacteria	  Signs and Symptoms 
Anthrax  Bacillus anthracis	  severe depression, inability to 
stand, tachypnea, and pale 
mucous membranes 
Enterotoxemia	  Clostridium perfringens 
Type A and C	  necropsy by hemorrhage 
loops of bowel and 
hemorrhagic gastritis 
Type D	  pulmonary congestion, 
petechial and ecchymotic 
hemorrhage of the lower neck 
and axillary space muscular, 
and a pericardial effusion 
containing a fibrinous clot 
Brucellosis  Brucella melitensis	  abortion 
B. abortus 
Tuberculosis	  Mycobacterium tuberculosis no proof of the tuberculosis 
M bovis, M avium,  diagnosis could be 
M micro!!  demonstrated following 
extensive histopathological 
and culture efforts 
Leptospirosis  Leptospira spp.	  hemolytic anemia, abortion 8 
Table 2.1 (Continued) 
Disease 
Alpaca Fever 
Bacteria  Signs and Symptoms 
Streptococcus zooepidemicus bacterial septicemia, elevated 
body temperatures(greater 
than 104°F), anorexia, 
weight loss, ascites, 
and relatively rapid death 
Johne's Disease  Mycobacterium 
paratuberculosis 
colonic granulomatus 
enteritis, chronic weight 
loss and loose feces 
Lumpy Jaw  Actinobacillus ligniersii 
Actinomyces spp. 
intermandibular swellings 
osteomyelitis 
Tetanus  Clostridium tetani  tonic spasm of voluntary 
muscle especially of the jaw 
Colibacillosis  Escherichia coli  diarrhea 
Listeriosis  Listeria monocytogenes  head tilt and tendency toward 
circling (signs of central 
nervous system ) 
Mastitis  E. coli  severe toxemia, systemic 
illness and loss one or more 
of the four-quartered 
mammary glands 9 
Table 2.1 (Continued) 
Disease  Bacteria  Signs and Symptoms 
Pinkeye  Staphylococcus aureus  keratoconjunctivitis (pinkeye) 
Moraxella liquefactions 
Dermatophilosis  Dermatophilis congolensis	  wool rot, lesions of moist 
crusting, particularly over 
the dorsum of the back 
Foot Rot	  Bacteroides fragilis  foot rot 
Fusobacterium necrophorum 
Abscesses	  Streptococcus equi  facial swellings 
Corynebacterium spp. 
Necrotic Stomatitis	  Fusobacterium necrophorum oral injuries 
Salmonellosis  Salmonella spp.	  explosive watery diarrhea and 
variable amounts of 
hemorrhage 10 
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1 - thiazolidine ring 
2-13-lactarn ring 
Rracyl side chain 
Figure 2.1 6-Aminopenicillanic Acid 11 
Pharmacokinetics and dosage regimen of ampicillin sodium given as single 
intravenous bolus has been determined in humans (Ripa et al., 1990), horses (Dun, 
1976), mice, dogs (Chang-Xio, 1991), sheep (Oukessou, 1992), kitten (Goldstein 
et al., 1995) and llamas (Christensen et al.  1996). The influence of drug 
formulation on ampicillin bioavailability and plasma concentrations was shown after 
intramuscular administration of five different parenteral ampicillin formulations to 
ruminant calves (Nouws et al., 1982). 
The objectives of this study were to determine the comparative 
pharmacokinetics of ampicillin following intramuscular administration, and to 
establish if the ampicillin trihydrate suspension can be absorbed from the 
intramuscular injection site. Since intramuscular administration is easily and 
frequently used as the route of choice over intravenous administration in the llama, 
it is appropriate to establish the pharmacokinetics following IM administration. 
Although ampicillin trihydrate formulations are cheaper than ampicillin sodium 
formulations, however some species (e.g. horse) cannot absorb the trihydrate form 
from the injection site. For this reasons, the bioavailability of ampicillin trihydrate 
needs to be determined in llamas. 
2.3. MATERIALS AND METHODS 
2.3.1 Materials and Reagents: 
Ampicillin and 13-hydroxyethyl theophylline were obtained from Sigma 
Chemical Co. (St. Louis, MO). Acetonitrile (HPLC grade), methanol (HPLC grade), 
phosphoric acid, and potassium phosphate, monobasic were obtained from Aldrich Chemical (Milwaukee, WI). Polypropylene centrifuge tubes, 1.5-m1 capacity were 
obtained from J.T. Baker Chemical Co. (Phillipsburg, NJ). 
Ampicillin standard solution, 1 mg/ml, was freshly prepared by dissolving 
25 mg of ampicillin in 25 ml of distilled water. Internal standard solution, 25 p.g/ml, 
was prepared by dissolving 25 mg of P-hydroxyethyl theophylline in 100 ml of 
distilled water. Ten ml of this solution was diluted to 100 ml with distilled water. 
Mobile phase consisted of 200 ml of methanol and 800 ml of 5 mM phosphate 
buffer (0.68 g of potassium phosphate, monobasic per liter of distilled water). The 
mobile phase pH was titrated to 4.7 with phosphoric acid, filtered through 0.47 
filter, and degassed by sonicating under vacuum for about 15 minutes. 
Parenteral solution of ampicillin sodium (Amp-equine®), and parenteral 
suspension of ampicillin trihydrate (Polyflex®) were obtained from Smith Kline 
Beecham (Exton, PA) and Fort Dodge Inc. (Fort Dodge, Iowa) respectively. 
2.3.2. Animals : 
Six sexually mature healthy llamas (3 males and 3 females) from the Oregon 
State University Camelid research herd, weighing between 120 and 175 kg, were 
used. All animals received routine health checks, including vaccination and 
deworming three times a year. No routine health treatments were performed within 
two weeks prior to the study's initiation. 
2.3.3. Sampling Protocol : 
An indwelling catheter was placed in the jugular vein and fitted with a 
catheter extension 24 hours before the start of the study. A local lidocaine block 
was used to minimize the discomfort associated with the catheter placement. Feed 13 
and water were available ad libitum. The catheter was flushed with 10 ml of 
heparinized saline solution once daily on non-sample days. The drugs were 
alternately administered at 12 mg/kg body weight/day as intramuscular injections 
into the semimembranosus hind muscle with a 72 hour wash out period between 
dosages. Blood samples were collected via the catheter immediately before drug 
administration and 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, and 
12 h after drug adminstration. The blood was transfered to evacuated tubes 
containing EDTA, and mixed thoroughly. After a blood sample was collected, the 
catheter was flushed with 10 ml of heparinized saline solution. Following collection, 
the blood sample was centrifuged, the plasma was decanted and then frozen at -20°C 
until assayed. 
2.3.4. HPLC Assay : 
The HPLC system consisted of an HPLC pump (Model M-600 A; Waters 
Associates, Inc., Milford, MA), a WISP autosampler (Model 710 B, Waters 
Associates, Inc.), a variable wavelength detector (Model SP8773 XR, Spectra 
Physics Inc.,), and a recorder (Linear Inc.) The drug was eluted on a Microsorb-
MV C18 column (Rainin Instrument Co.) with a flow rate of 1.0 ml/min. The 
detector was set at a wavelength of 250 nm with a sensitivity at 0.05 absorbance 
units. The recorder chart speed was set at 6 cm/h receiving signal from the UV 
detector at a 10 mV maximum scale. 
Ampicillin was assayed following a method that was modified from the 
method of Mazro et al. (1990). To a 0.5 ml of plasma ampicillin sample, 50 pl of 
13-hydroxyethyl theophylline as an internal standard solution was added in a 1.5-m1 
polypropylene centrifuge tube, and vortex mixed. To the ampicillin, P-hydroxyethyl 
theophylline plasma sample, 1.0 ml of acetonitrile was added, vortex mixed 14 
vigorously for 1 min, and centrifuged at 14,000 g for 5 min.  1.3 ml of the resultant 
supernatant was decanted into another labeled 1.5-m1 polypropylene tube, and 
evaporated in a vacuum chamber at room temperature for 4 h. 150 pl of the 
remaining solution was injected onto the HPLC system. Peaks of the ampicillin and 
13-hydroxyethyl theophylline were clearly separated with mean retention times at 15 
and 11 min respectively. 
Plasma ampicillin standard solutions of concentrations of 0, 1, 2.5, 5, 10, 
25, and 50 pg/m1 were made by serial dilutions from the standard ampicillin 
solution, 1 mg/ml with blank (drug free) llama plasma, and assayed as described to 
obtain a standard curve to measure the unknown samples. Three standard curves 
were run over a period of three weeks to assure the assays performed were accurate. 
The standard curves superimposed over each other indicating that the assay was 
stable, reproducible and independent of minor human and machine fluctuations. 
The standard curves were analyzed by regression analysis with least sum of 
squares of peak height ratios over the concentrations of the standard solution. The 
ampicillin sample concentrations were calculated by using the regression results of 
the standard curves. 
2.3.5. Pharmacokinetic Analysis : 
Plasma concentrations vs. time data were analyzed using RSTRIP Computer 
Software (1992) to fit the data. The data fitted using the weighting 1/(plasma 
concentration) gave best fit over fitting the plasma concentration time curve with 
equally weighted or weighted 1/(plasma concentration)2 (Wagner, 1975). 
The plasma concentrations as a function of time after IM administration in 
each llama were fitted to polyexponential equations. Nonlinear least squares fit of 
each data set followed the general equation : 15 
Cp =  e "xit  Eq. 2.1 
Where C, is the ampicillin plasma concentration, Xi are the exponents, Ai are the 
preexponential coefficients and t is time. The number of terms required (A X ) for 
each subject was determined by the analysis of Model Selection Criterion (MSC) 
value. 
Both compartmental model dependent pharmacokinetic parameters of A, 
Ka, Kei, half-life (t112) and apparent volume of distribution (Vd) and non-
compartmental model pharmacokinetic parameters of area under the curve (AUC), 
area under the moment curve (AUMC), mean residence time (MRT) and body 
clearance (CL) (Baggot, 1977; Gibaldi et al., 1988; Rowland et al.,  1989; Wagner, 
1979; Dunne et al.,  1989; Wagner, 1976; Yamaoka, 1978; Vancutsen et al.; Hadi, 
1994) were determined by RSTRIP computer software. 
2.4. RESULTS 
Ampicillin plasma concentrations of the ampicillin sodium salt, their means 
and standard deviations at each sampling time are shown in table 2.2. The ampicillin 
plasma concentrations of the ampicillin trihydrate were too low to be quantified by 
the described assay method. 
Ampicillin plasma concentration versus time curves of each llama were 
analyzed individually by RSTRIP computer software with a weighting factor of 
1/plasma concentration and 1/(plasma concentration)2. The mean values and 
standard deviations of the pharmacokinetic parameters were computed and are 
shown in table 2.3 and table 2.4 respectively. 
The data of six llamas was best fit using a biexponential function describing 
the declining ampicillin plasma concentrations as a function of time  : 16 
Cp = A ( e"),2` -
e-xii.)  Eq. 2.2 
where Cp is the ampicillin plasma concentration, X or Ka and X2 or Kel are 
absorption and elimination rate constants respectively and t is the time. 
The time curves of the ampicillin plasma concentrations of individual 
llamas and the mean concentration time curve in llamas after IM administration 
are shown in figure 2.2 and figure 2.3 respectively. 
Pharmacokinetics of ampicillin after intramuscular administration in all 
llamas followed (correlation coefficient > 0.99) a biexponential equation, with first 
order absorption and first order elimination rate constants, Ka of 69.45 ± 47.34 
hours-1 and Kei of 0.86 ± 0.28 hours"1 respectively. The elimination half-life (t112) 
and mean residence time were 0.81 ± 0.31 hours (h) and 1.405 ± 0.41 hours 
respectively. The peak concentration (C,,.) and the time to reach peak plasma 
concentration (tn.) were 14.82 ± 5.96 lag/m1 and 0.13 ± 0.12 hours respectively. 
The apparent volume of distribution and the body clearance were 0.78 ± 0.19 Ukg 
and 0.58 ± 0.27 Ukg/h respectively. 
The data were also fitted by WINNONLIN computer software. Each plasma-
concentration time profile of all llamas was fitted to triexponential equation or two 
compartment model with a first order input with weighted 1/(plasma concentration)2. 
The mean plasma concentration time curve and the predicted line are shown in figure 
2.4. The pharmacokinetic parameters are shown in table 2.5. 17 
Table 2.2. Ampicillin Plasma Concentrations (µg/ml) vs Times (hours) after 
Intramuscular Administration (12 mg/kg over 1-2 min.) in Llamas 
Time  Drug Plasma Concentrations (tg/m1) 
(hours) Llamal  Llama2  Llama3  Llama4  Llama5  Llama6  Mean  SD 
0  0.0  0.0  0.0  0.0  0.0  0.0  0.0  0.0 
0.25  11.89  10.11  9.78  16.27  22.83  12.43  13.80  5.00 
0.5  10.14  8.32  9.15  13.27  15.94  10.53  11.23  2.86 
0.75  7.64  6.88  6.88  9.64  14.04  9.81  9.15  2.73 
1.0  6.55  5.48  4.51  8.38  10.95  7.75  7.27  2.30 
1.5  3.21  3.75  2.37  5.68  6.71  5.91  4.60  1.73 
2  1.89  2.08  1.41  4.16  4.31  4.84  3.11  1.48 
3  1.25  1.18  0.52  2.65  2.86  3.41  1.98  1.48 
4  0.24  0.89  0.13  1.51  1.77  2.37  1.15  0.89 
6  ND  ND  ND  0.69  1.49  1.72  1.30  0.54 
8  ND  ND  ND  ND  ND  ND 
12  ND  ND  ND  ND  ND  ND 18 
Table 2.3.  Pharmacokinetic Parameters for Ampicillin Sodium after 
Intramuscular Administration (12 mg/kg over 1-2 min.) in Llamas. 
Parameter  Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean SD 
A  lig/m1  17.03  12.17  17.22  17.36  27.47  13.55  17.47  5.36 
Ka  9.17  100.00  7.51  100.00  100.00  100.00  69.45  47.34 
Kei  1.04  0.79  1.26  0.67  0.91  0.49  0.86  0.28 
t1/2  0.67  0.88  0.55  1.04  0.76  1.42  0.81  0.31 
tmax  h  0.27  0.05  0.29  0.05  0.05  0.05  0.13  0.12 
Cmax  pg/m1  11.44  11.62  9.99  16.68  26.07  13.14  14.82  5.96 
AUC  .1,8.h/m1  14.56  15.35  11.34  25.93  29.82  27.72  20.79  7.92 
AUMC  ug.h2/m1  15.63  19.66  10.50  39.25  32.96  57.24  29.21  17.47 
MRT  h  1.07  1.28  0.93  1.51  1.11  2.07  1.405  0.41 
Vd  1/kg  0.79  0.99  0.84  0.70  0.44  0.89  0.78  0.19 
CL  l/kg/h  0.82  0.78  1.06  0.46  0.40  0.43  0.58  0.27 19 
Table 2.4. Pharmacokinetics parameters of ampicillin after IM injection at a 
dose of 12 mg/kg fitted with and weighted 1/(plasma concentration)2 
Para- Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6  Mean  SD 
meter 
A  ..1,g/m1  16.76  11.07  15.60  14.51  18.02  11.39  14.56  2.83 
Ka  9.71  100.00  9.07  100.00  100.00  100.00  69.80  46.79 
Kei  11-1  1.04  0.72  1.19  0.55  0.57  0.37  0.74  0.31 
Cmax  µg/ml  11.46  10.60  9.98  14.03  17.39  11.11  12.43  2.80 
tmax  h  0.26  0.05  0.26  0.05  0.05  0.06  0.12  0.11 
t112  h  0.67  0.96  0.58  1.27  1.27  1.89  0.94  0.48 
AUC  pg.h/m1  14.45  15.27  11.40  26.37  31.32  30.91  21.62  8.94 
AUMC  tg.h2 /m1  15.43  21.38  10.84  48.44  55.07  84.54  39.28  28.56 
MRT  h  1.07  1.40  0.95  1.84  1.76  2.73  1.62  0.65 
Vd  1/kg  0.80  1.09  0.89  0.83  0.67  1.06  0.89  0.16 
CL  1/kg/h  0.83  0.79  1.05  0.46  0.38  0.39  0.56  0.28 10 
0.1 
20 
1 2  3 4  5 6 
Time After Dose (Hours) 
Figure 2.2. Ampicillin plasma concentration time curves 
after 12 mg/kg IM administration of 6 llamas 
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Table2.5. Pharmacokinetic parameters of ampicillin after IM injection at a dose of 
12 mg/kg fitted with WINNONLIN and weighted 1/(plasma concentration)2 
Parameter Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
Al  µg/ml  13.13  3.30  4.77  13.05  26.76  11.96  12.16  8.34 
A2  µg/ml  3.62  15.00  21.00  8.46  1.78  2.60  8.74  7.77 
11-1  1.04  2.50  4.00  1.59  1.11  0.76  1.83  1.23 
X2  1.03  1.00  1.60  0.42  0.04  0.08  0.70  0.62 
Ka  111  9.71  199.0  1989.0  1988.0  1987.0  1986.0 1359.8  974.3 
K10  1.04  1.12  1.80  0.76  0.38  0.31  0.90  0.55 
K12  0.00  0.15  0.24  0.37  0.66  0.33  0.29  0.22 
K21  1.04  2.23  3.56  0.88  0.10  0.20  1.34  1.33 
AUC  lig/1/h  14.44  16.23  14.30  28.29  74.15  47.37  32.46 24.07 
t1 /2,1  h  0.67  0.28  0.17  0.44  0.63  0.91  0.38  0.27 
t1/42  h  0.67  0.69  0.43  1.65  19.48  8.44  1.00  7.62 
Vd  1/kg  0.80  0.66  0.47  0.56  0.42  0.82  0.62  0.17 
CL  l/h/kg  0.83  0.74  0.84  0.42  0.16  0.25  0.37  0.30 
Trim  0.26  0.03  0.00  0.00  0.00  0.00  0.05  0.10
C.  14/m1  11.45  17.60  25.56  21.41  28.41  14.52  19.83  6.52 100 
23 
10 
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Figure 2.4. Mean plasma concentration-time curve of ampicillin after 
12 mg/kg IM injection fitted with WINNONLIN and weighted 
1/(plasma concentration)2 24 
2.5. DISCUSSION AND CONCLUSION 
Pharmacokinetics of ampicillin after a single IM administration at 12 mg/kg 
fitted by RSTRIP with weighted 1/plasma concentration was one-compartment 
model with first order aborption rate constant(Ka) of 69.45 ± 47.34 III and first 
order elimination rate constant(Kni) of 0.86 ± 0.28 111, whereas that of ampicillin 
after single IV bolus administration at the same dose was two-compartment model 
with first order elimination rate constant(Kni) of 0.58 ± 0.42 11-1 (Christensen, 1996). 
The harmonic mean elimination half-life (t112) in llamas after IM 
administration was 0.81 ± 0.31 h, whereas half-lives of 1.7, 2.1, 3.3, 22.2, and 
11.9 h have been reported for ruminant calves after IM administration of five 
different parenteral ampicillin formulations (Nouws et al., 1982) and half-lives of 
3.33, 1.09, 0.79, 0.71, 0.96, and 1.6 h have been reported for llamas, humans, sheep, 
goats, mice, and horses respectively after single IV bolus administration (Christensen, 
1996; Dun-, 1976; Ripa et al., 1990; Escudero, 1996; Chang et al., 1991; Oukessou 
and Toutain, 1992). The mean peak plasma concentration (Cmax) in llamas after IM 
administration was 14.82 ± 5.96 µg/ml at 0.13 ± 0.12 h, whereas the Cmax of 4.6, 3.5, 
1.8, 0.6, and 0.4 vg/m1 at 1 to 1.5 hours have been reported for ruminant calves after 
IM administration of five different parenteral ampicillin formulations at the dose of 
4 mg/kg body weight (Nouws et al., 1982). The Cmax of ampicillin sodium at a dose 
of 13.33 mg/kg body weight after IM injection were 10.61 and 9.171.1g/m1 in sheep 
and goats respectively (Escudero, 1996). The apparent volume of distribution in 
llamas after IM injection was 0.78 ± 0.19 1/kg whereas the Vasa of 0.277, 0.269, 
0.156, 0.377, and 2.51 1/kg have been reported for llamas, human, sheep, mice, and 
horse after IV bolus injection ( Christensen, 1996; Oukessou, 1992; Chang et al, 
1991; Dun-, 1976; Ripa, 1990). The body clearance in llamas after IM administration 
was 0.58 ± 0.27 l/kg/h whereas the body clearance of 0.053 ± 0.017 l/kg/h has been 
reported for llamas after IV bolus injection at the dose of 12 mg/kg (Christensen, 25 
1996) and of 3.0 to 3.84 l/kg/h for sheep after IM injection at a dose of 10 mg/kg 
(Nawaz, 1989). The C. of ampicillin trihydrate at a dose of 12 mg/kg after IM 
administration in llamas was less than 0.1 µg/ml, which was similar in horses, 
whereas, the C. of 2.5 ± 0.54 pg/m1 at 2 h has been reported in calves at a dose 
of 10 mg/kg (Brown, 1991). It is apparent that the absorption and elimination of 
ampicillin is affected by the chemical forms, formulations, routes of administration 
and species of animals. Ampicillin trihydrate is considerably less soluble than 
ampicillin sodium. The absorption of ampicillin from its trihydrate form appears to 
be quite slow preventing therapeutic concentrations to be achieved not only in 
llamas but other species. 
The plasma concentration time profiles of ampicillin sodium of six llamas 
showed statistical difference of two groups. First group is male, faster three 
eliminators and the other is female, slow three eliminators. The results of fitting 
with RSTRIP and WINNONLIN weighted 1/(plasma concentration)2 are shown in 
table 2.4 and 2.5 respectively. 
The dose and dosing interval of ampicillin given intravenously in sheep is 
10 mg/kg/day, 40 mg/kg/day in horses, and 12 mg/kg/day or 6 mg/kg every 12 h 
in llamas (Christensen, 1996). In humans, ampicillin dosing administration is 2 to 
4 g per day, divided into equal portions and given every 6 hours orally for mild to 
moderately severe disease, and 6 to 12 g per day or 1.5 to 3 g every 6 hours 
parenterally for severe infections. To acheive an MIC of 1-3 p.g/ml, ampicillin 
sodium solution administered intramuscularly into llamas should be given at a dose 
of 12 mg/kg of body weight, every 6 h for the Cmax (peak) and Cniin (trough) 
plasma concentration of 10 to 16 µg/ml and 1.0 p.g/ml. The appropriate dosing 
regimen for IM inejection in llamas should be 24 mg/kg every 12 hours or 12 mg/kg 
every 6 hours. 26 
The intramuscular administration is much easier and more commonly used 
than intravenous administration and can be an alternate route providing the 
therapeutic plasma concentrations. The cheaper ampicillin trihydrate should not be 
used in llamas due to its inability to be absorbed quickly enough to produce 
measurable plasma concentrations. 27 
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CHAPTER 3
 
PHARMACOKINETICS OF GENTAMICIN GIVEN IV BOLUS 
MULTIPLE DOSES AND AMIKACIN GIVEN SINGLE IV BOLUS 
AND IM DOSES IN LLAMAS 
3.1. ABSTRACT 
Pharmacokinetics of amikacin after single IM and IV bolus doses and 
gentamicin given by IV bolus injection for four doses consecutively were 
investigated. The pharmacokinetic parameters for gentamicin of half-life, AUC, 
CL, and Vass from four doses are not statistically significantly different ( p > 0.05). 
The mean plasma concentration versus time profiles of the first dose and the fourth, 
assumed to be at the steady state, were statistically not significantly differrent 
(p = 0.06). The elimination half-life (t1,20) was 2.27 ± 0.13 h following the first dose 
of drug administration. The mean body clearance was 0.12 ± 0.02 1/h/kg. The 
mean apparent volume of distribution (Yd.) was 0.39 ± 0.08 1 /kg. A predicted 
dosage regimen in the llamas of 4 mg/kg body weight once daily or 1 mg/kg every 
8 hours administered parentally should provide practical therapy of a peak plasma 
concentration at steady state of 10 µg/ml, and trough concentration less than 
2 lag/ml. 
The absorption rate constant(Ka ) of amikacin after single IM administration 
at 12 mg/kg was 3.75 ± 0.15 111 and elimination rate constant(Kel) was 
0.27 ± 0.01 111, whereas the elimination rate constant of amikacin after single IV 
bolus administration at the same dose was 0.25 ± 0.01  No statistically 
significant differences (p > 0.05) were observed for any of the pharmacokinetic 
parameters between IM and IV administrations. The mean elimination half-life(t1/2,2) 31 
of amikacin in llamas and the mean body clearance were 2.77 ± 0.18 h and 
2.60 ± 0.14 h and were 0.08 ± 0.01 l/kg/h and 0.09 ± 0.01 l/h/kg after IV and IM 
administrations respectively. The apparent volume of distribution (Vdss) was 
0.33 ± 0.04 and 0.34 ± 0.04 1/kg after IV and IM administrations respectively. 
A dosage regimen in the llamas of 12 mg/kg body weight once daily or 4 mg/kg 
every 8 hours administered intravenously or intramuscularly should provide 
adequate therapy of a peak at the steady state of 35 tg/m1 and trough 
concentration of less than 10 µg/ml. 
3.2. INTRODUCTION 
Aminoglycoside class of antibiotics contains a pharmacophoric 1, 3­
diaminoinositol derivative : streptamine, 2-deoxystreptamine, or spectinamine 
(Figure 3.1). Some of the alcoholic functions of these are substituted through 
glycosidic bonds with characteristic aminosugars to form pseudo-oligosaccharides. 
The chemistry, spectrum, potency, toxicity, and pharmacokinetics of these agents 
are a function of the specific identity of the diaminoinositol unit and the 
arrangement of the attachments. 
The aminoglycosides are freely water soluble at all achievable pH's, are 
basic and form acid addition salts, are not absorbed in significant amounts from 
the gastrointestinal tract, and are excreted in their active form in fairly high 
concentrations into the urine. When the kidneys are not functioning efficiently, the 
dose of the aminoglycosides administered by injection must be reduced to prevent 
accumulation of drug to toxic levels. If aminoglycosides are given orally, their 
action is primarily confined to the gastrointestinal tract (Foye et al, 1995). The 
aminoglycosides have been used routinely in human to sterilize the large intestine prior to surgery. In humans, a once daily dosage regime of neomycin was used to 
produce intra-operative suppression of the gastrointestinal flora (Horspool et al., 
1994). They are more commonly given intravenously or intramuscularly or by 
perfusion to treat systemic infections. 
Aminoglycosides have an intrinsically broad antimicrobial spectra but their 
toxicity potential limits their clinical use to severe infections by gram-negative 
bacteria. They display trough concentration-dependent reversible nephrotoxicity 
and commonly irreversible ototoxicity in human, which may present itself after 
treatment ceases (Kumana et al., 1994). The toxicity of ototoxicity involves 
functions mediated by the eighth cranial nerve, specifically as hearing loss and 
vertigo. The kidney tubular necrosis produced decreases glomerular function. 
These toxic effects are related to blood concentrations and are apparently mediated 
by the special affinity of the aminoglycosides to kidney cells and to the sensory cells 
of the inner ear. The effects may have a delayed onset, making them all the more 
treacherous as the patient can be significantly injured before symptoms appear. 
Aminoglycosides are widely distributed throughout the body (mainly in 
extracellular fluids) and have low levels of protein binding. Aminoglycosides are 
highly polar and apparently bind initially to external liposaccharides. They diffuse 
into the cells in small amounts through the porins, and bind to the protein portion 
of the 30S ribosomal subunit leading to mistranslation of RNA templates, 
consequently causing insertion of wrong amino acids leading to the formation of 
nonsense proteins or nonnatural proteins. This results in disruption of the membrane 
permeability lead to cellular death. This damage cannot be repaired by the bacteria 
without de novo programmed protein biosynthesis (Foye et al., 1995). 33 
Amikacin is made semisynthetically from kanamycin and has enhanced 
potency and spectrum (Foye, 1995). Amikacin has potent activity against gram-
negative bacteria, including Pseudomons aeruginosa, and non-beta-lactamase 
and beta-lactamase producing staphylococci and retains its antimicrobial activity 
in the presence of approximately 90% of the enzymes which destroy other 
aminoglycosides (Caudle et al., 1983; Gingerich et al., 1983) making amikacin 
the least susceptible to degradation by bacterial enzymes (Kumana et al., 1994). 
Amikacin is excreted entirely by glomerular filtration and is reabsorbed in 
the proximal tubule. The half-life of the drug is approximately 2 hours in human 
patients with normal renal function. Therapeutically useful serum concentrations 
obtained are typically four to five times greater than with gentamicin and tobramycin. 
Tissue distribution of amikacin is similar to that of other aminoglycosides except that 
more appears to be concentrated in adipose tissue (Kagan, 1980). In most cases, the 
minimum inhibition concentration (MIC) of a susceptible gram-negative bacterium, 
including Pseudomonas aeruginosa, Bacteroides spp., Klebsiella pneumoniae, 
Salmonella typhimurium, and Rhodococcus (Corynebacterium) equi, is less than or 
equal to 4 p.g/m1 amikacin (Orsini et al., 1985; Baggot & Prescott, 1987; Hirsh & 
Jang, 1987). 
Gentamicin is a mixture of three aminoglycosides: gentamicins C-1, C-2, 
and C-la. Gentamicin was one of the first antibiotics to have significant activity 
against Pseudomonas aeruginosa infections. Gentamicin is the usual all-purpose 34 
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agent of choice (Kumana et al., 1994) used for urinary tract infections, burns, some 
pneumonias, and bone and joint infections caused by susceptible gram-negative 
organisms. It is often used to prevent fouling of soft contact lenses. It is also used 
in polymer matrices in orthopedic surgery to prevent sealed in sepsis.  It is given 
topically, sometimes in special dressings, to burn patients (Foye et al., 1995). The 
physicochemical properties of gentamicin, like other aminoglycoside antibiotics, 
determine its pharmacokinetic behavior in the body (Hadi et al., 1994). The 
pharmacokinetics of gentamicin have been reported in humans (Garg et al., 1995), 
buffalo calves (Bubalus bubalis) (Garg et al, 1992), goats (Ahmad et al., 1994), 
horses (Godber, 1995), cockatiels (Ramsay & Vulliet, 1993) sheep, cows (Hadi 
et al., 1994) and llamas (Lackey et al., 1996). 
The objective of this study was to determine the pharmacokinetics of 
intravenous and intramuscular amikacin and multiple IV dose of gentamicin. 
Amikacin is rapidly becoming the aminoglycoside of choice for a number of 
infectious agents. Based on gentamicin and tobramycin results (Christensen, 1996; 
Lackey et al, 1996), an amikacin dosage of 12 mg/kg/day should be appropriate to 
get peak and trough plasma concentrations of 25-301.1g/m1 and less than 10 pg/m1 
respectively. This dosage needs, however, to be confirmed with single dose IV and 
IM pharmacokinetic studies. 
Although gentamicin pharmacokinetics have been done in llamas, due to the 
potential for nephrotoxicity, it is important to determine the dosage regimen from 
pharmacokinetic disposition after multiple dose administration of the drug in llamas. 
Peak and trough concentrations of 6-1014/m1 and less than 2 pg/m1 respectively are 
expected from a 4 mg/kg/day dose. Therefore, the objective of this study was to 36 
confirm that repeated gentamicin dosing at 3.2 mg/kg body weight/day would 
produce appropriate peak and trough drug concentrations at steady state. 
3.3. MATERIALS AND METHODS 
3.3.1. Materials and Reagents : 
Gentamicin sulfate was obtained from Spectrum Chemical Manufacturers 
Corp.(Gardena, CA). Amikacin, tobramycin, tris (hydroxymethyl) aminomethane, 
2,4,6-trinitrobenzene-l-sulfonic acid (TNBSA), and sodium octane sulfonate were 
obtained from Sigma Chemical Co. (St. Louis, MO). Acetonitrile (HPLC grade), 
phosphoric acid, and potassium phosphate, monobasic were obtained from Aldrich 
Chemical (Milwaukee, WI). Polypropylene centrifuge tubes, 1.5-m1 capacity, and 
the C-18 solid-phase extraction columns were obtained from J.T. Baker 
Chemical Co. (Phillipsburg, NJ), and the Vac-Elut vacuum chamber was obtained 
from Analytichem International, Inc. (Harbor City, CA). 
3.3.1.1. For both gentamicin and amikacin assays : 
Tris buffer, 2 M, pH 10.3, was prepared by dissolving 24.2 g of 
tris (hydroxymethyl) aminomethane in 100 ml of distilled water. Internal standard 
solution, 100 µg/ml, was prepared by dissolving 25 mg of tobramycin sulfate in 
25 ml of distilled water. Ten ml of this solution was diluted to 100 ml with distilled 
water. 
3.3.1.2. For gentamicin assay 
2,4,6- trinitrobenzene -1- sulfonic acid (TNBSA) derivatizing solution, 400 
mg/ml, was prepared by dissolving 4 g of TNBSA (Sigma) in 10 ml of acetonitrile. 37 
Stock gentamicin solution, 1 mg/ml, was prepared by dissolving 25 mg of gentamicin 
in 25 ml of distilled water. 
Stock Wash Buffer, 1 M, was prepared by dissolving 17.4 g of potassium 
phosphate, monobasic in 100 ml of distilled water. Working Wash Solution, a 
methanol/phosphate buffer solution (0.1 M, pH 8.5, 50/50 V/V), was prepared by 
using 10 ml of the stock wash buffer, adding 90 ml of distilled water, and mixing 
with 100 ml of methanol. pH of this solution was adjusted to 8.5 with 3M sodium 
hydroxide (6 g of sodium hydroxide in 50 ml of distilled water). 
Mobile phase for HPLC analysis of gentamicin consisted of 700 ml of 
acetonitrile and 300 ml of 5 mM phosphate buffer and 2 mM of sodium octane 
sulfonate (0.68 g of potassium phosphate, monobasic and 0.13 g of sodium octane 
sulfonate per liter of distilled water). The mobile phase was titrated pH to 3.5 with 
phosphoric acid, filtered through 0.47 pm filter, and degassed under vacuum with 
concurrent sonication for about 15 minutes. 
Parenteral solution of gentamicin sulfate, 3.2 %, was prepared by dissolving 
32 g of gentamicin sulfate in 1 liter of normal saline for injection. The solution was 
filtered through 0.2 pm filter fitted directly to a sterile syringe. 
3.3.1.3. For amikacin assay : 
2,4,6-trinitrobenzene-l-sulfonic acid ( TNBSA) derivatizing solution, 250 
mg/ml, was prepared by dissolving 2.5 g of TNBSA (Sigma) in 10 ml of acetonitrile. 
Stock amikacin solution, 1 mg/ml, was prepared by dissolving 25 mg of amikacin in 25 
ml of distilled water. 
Wash Buffer, 10 mM, was prepared by dissolving 1.82 g of potassium 
phosphate, monobasic in 1 liter of distilled water. The pH of this solution was 
adjusted to 8.6 with 3 M sodium hydroxide (6 g of sodium hydroxide in 50 ml of 
distilled water). 38 
Mobile phase consisted of 470 ml of acetonitrile and 530 ml of 20 mM 
phosphate buffer (2.72 g of potassium phosphate, monobasic per liter of distilled 
water). The mobile phase was titrated pH to 3.0 with phosphoric acid, filtered 
through 0.47 p.m filter, degassed under vacuum while sonicating for about 
15 minutes. 
Parenteral solution of amikacin sulfate, (250 mg/ml) Amiglyde-r was 
obtained from Fort Dodge Inc. (Fort Dodge, Iowa). 
3.3.2. Animals : 
In the amikacin study, four sexually mature healthy llamas (2 males and 2 
females) and 2 sexually mature healthy alpacas (males) from the Oregon State 
University Camelid research herd, weighing between 150 and 185 kg for llamas, 
and between 58 and 64 kg for alpacas were used. 
In gentamicin study, six sexually mature healthy llamas (3 males and 
3 females) from the Oregon State University Camelid research herd, weighing 
between 120 and 175 kg, were used. All animals receive routine health checks, 
ncluding vaccination and deworming three times a year. No routine health 
treatments were performed within two weeks of the study's initiation. 
3.3.3. Sampling Protocol : 
An indwelling catheter was placed in the jugular vein and fitted with a 
catheter extension 24 hours before the start of the study. A local lidocaine block 
was used to minimize the discomfort associated with the catheter placement. 
Feed and water were available ad libitum. The catheter was flushed once daily 
with 10 ml of heparinized saline solution on non-sample days. 39 
Amikacin was administered as an intravenous injection into the jugular vein 
over a 1-2 min period and as an intramuscular injection into the semimembranosus 
hind muscle at 12 mg/kg body weight/day with a 72 wash out period between 
dosages. The llamas were chosen in random order to receive the injection on drug 
administration days. Blood samples were collected via the catheter immediately 
before drug administrations and 5 min,15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 
8 h, and 12 h after the drug administration. 
Gentamicin was administered as an intravenous injection of 3.2 mg/kg body 
weight/day into the jugular vein in each llama over a 1-2 min period at 24-h 
intervals for 4 days. The order in which the llama's received the gentamicin daily 
injections was performed at random. Blood samples were collected via the catheter 
immediately before drug administration and 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 
and 12 h after the first dose, and 30 min, 1 h, 4 h, 8 h, and 12 h after the later three 
doses. 
The collected blood was transfered into evacuated tubes containing EDTA, 
and mixed thoroughly. After a blood sample was collected, the catheter was flushed 
with 10 ml of heparinized saline solution. Following collection, the blood sample 
was centrifuged, the plasma was decanted and frozen at -20°C until assayed. 
3.3.4. HPLC Assay : 
The HPLC system consisted of an HPLC pump (Model M-600 A; Waters 
Associates, Inc., Milford, MA), a WISP autosampler (Model 710 B, Waters 
Associates, Inc.), a variable wavelength detector (Model SP8773 XR, Spectra 
Physics Inc.,), and a recorder (Linear Inc.)  Gentamicin was eluted on a 40 
Microsorb-MV C18 column (Rainin Instrument Co.) with a flow rate of 1.0 ml/min, 
detected at wavelength of 340 nm and sensitivity at 0.02 and 0.01 absorbance units, 
and recorded at chart speed of 10 cm/h receiving a signal from the detector at a 5 
and 2 mV scale for the gentamicin concentrations between 5 and 50 lig/ml, and 
between 0.1 and 2.5 µg/ml respectively. Amikacin was eluted on a Microsorb-MV 
C18 column (Rainin Instrument Co.) with a flow rate of 1.3 ml/min, detected at 
wavelength of 340 nm and sensitivity at 0.03 absorbance units, and recorded at 
chart speed of 10 cm/h received signal from the detector at a 5 mV scale. 
The assay method for gentamicin was modified from the method of Kabra 
et al. (1983). Twenty five p.1 of the internal standard solution, 1001.1g/m1 
tobramycin sulfate and 0.4 ml of gentamicin plasma samples were added together in 
1.5-ml polypropylene centrifuge tubes, and vortex mixed. 0.8 ml of acetonitrile was 
added, vortex mixed vigorously, and centrifuged at 14,000g for 5 min in an 
Eppendorf centrifuge (Model 5415 C). The supernatant was decanted and added 
to a second set of appropriately labeled polypropylene tubes, and 90 p.1 of 2-M tris 
buffer and 300111 of TNBSA were added. Tubes were capped, vortex mixed, and 
heated at 70°C for 30 min in a hot air oven for gentamicin and tobramycin 
derivatization. For each sample, a C-18 solid phase extraction column was placed 
on the top of Vac-Elut vacuum chamber and vacuum was connected to the chamber. 
Two column volumes of methanol and two column volumes distilled water were 
passed through each column. The vacuum was disconnected and each column was 
filled with 200 41 of working wash solution, followed by approximately 1 ml of the 
derivatized gentamicin sample. Vacuum was reconnected to chamber and three 
column volumes of working wash solution was passed through each column. 
Vacuum was disconnected and a rack of labeled glass tubes were placed on the 
Vac-Elut chamber, corresponding to each column. Then 300 !_t1 of acetonitrile 
was pipetted onto each column and vacuum was reconnected. After collecting 41 
the eluate in the tubes and vortex mixing, 200 tl of the extracted sample was 
injected onto the HPLC system. 
Two sets of gentamicin standard solution at concentrations of 0, 0.1, 0.25, 
0.5, 1, and 2.5 pg/m1 and of 0, 5, 10, 25, and 50 mg/m1 were made by serial dilutions 
of the stock gentamicin solution with blank (drug free) llama plasma. Gentamicin 
standard plasma solutions were derivatized and extracted as described for the 
unknown samples with conditions of the sensitivity of the detector and the recorder 
as described before. Six standard curves were run over a period of three weeks 
ensuring assay stability. Peaks of gentamicin and tobramycin were clearly separated 
and eluted within 25 min. Mean retention time for tobramycin, the internal standard, 
was 8 min and the gentamicin retention times for the three peaks were 16, 20, and 
23.5 min. 
The assay method for amikacin used was modified from the method of 
Kabra et al. (1984). Twenty five p1 of the internal standard solution, 100 pg/m1 
tobramycin sulfate, and 50 tl of amikacin plasma samples were added together in 
1.5-m1 polypropylene centrifuge tubes, and vortex mixed. Then, 100 p1 of 
acetonitrile was added, vortex mixed vigorously, and centrifuged at 14,000xg for 
2 min in an Eppendorf centrifuge (Model 5415 C). The supernatant was placed 
into a second set of appropriately labeled polypropylene tubes, and 25 µl of 2-M 
tris buffer and 30 p.1 of TNBSA were added. Tubes were capped, vortex mixed, 
and heated at 70°C for 30 min in a hot air oven to derivatize the amikacin and 
tobramycin. For each sample, a C-18 solid phase extraction column was placed on 
the top of Vac-Elut vacuum chamber and the vacuum was connected to the 
chamber. Two column volumes of methanol and two column volumes of distilled 
water were passed through each column. The vacuum was disconnected and each 
column was filled with 700 pl of working wash solution, followed by approximately 
250 ml of derivatized sample. Vacuum was reconnected to chamber and three 42 
column volumes of working wash solution was passed through each column. The 
vacuum was disconnected and a rack of labeled glass tubes were placed on the 
Vac-Elut chamber, corresponding to each column. Then 300 pl of acetonitrile was 
pipetted onto each column and the vacuum was reconnected. After collecting the 
eluate in the tubes and vortex mixing, 150 pl of the extracted sample was injected 
onto the HPLC system. 
A set of amikacin standard solutions of concentrations of 0, 5, 10, 25, and 
501,1g/m1 were made by serial dilutions of the stock amikacin solution with blank 
(drug free) llama plasma. The amikacin standard solutions were derivatized and 
extracted as described for the unknown samples. Three standard curves were run 
over a period of three weeks. Peaks of amikacin and tobramycin were clearly 
separated and eluted within 30 min. Mean retention times for tobramycin, the 
internal standard and amikacin were 24 and 28 min respectively. 
The standard curves were prepared by regression analysis with least sum of 
squares of peak height ratios over the concentrations of the standard solution. 
The sample concentrations were calculated by using the regression results of the 
standard curves. 
3.3.5. Pharmacokinetic Analysis : 
Plasma concentrations versus time data were analyzed using RSTRIP 
Computer Software (1992) to fit the data. Amikacin and gentamicin plasma 
concentration versus time curves of each llama were analyzed individually. 
The data was weighted 1/(plasma concentration) to get the best fit rather than 
equally weighted plasma concentration or wieghted 1/(plasma concentration)2 
(Wagner, 1975). 43 
The plasma concentrations as a function of time after IV bolus 
administration in each llama were fitted to polyexponential equations. Nonlinear 
least squares fit of each data set to a general equation : 
Cp =  e "kit  Eq. 3.1 
was obtained by using the number of terms required for each subject. C, is the 
amikacin or gentamicin plasma concentration, X are the exponents, Ai are the 
preexponential coefficients and t is time. 
Both the compartmental model dependent pharmacokinetic parameters of 
A1, A2, X1, X2, the volume of central or plasma compartment (Vc or Vp), 
half-life (t112) and the elimination rate constant (Kei) and the non-compartmental 
model pharmacokinetic parameters of area under the curve (AUC), area under the 
moment curve (AUMC), mean residence time (MRT), the apparent volume of 
distribution at the steady state (Vdss) and body clearance (CL) (Baggot, 1977; 
Gibaldi et al., 1988; Rowland et al., 1989; Wagner, 1979; Dunne et al., 1989; 
Wagner, 1976; Yamaoka, 1978; Vancutsen et al., 1990; Hadi et al., 1994) were 
determined by the RSTRIP computer software. 
Similarly for IM administration, both the compartmental model dependent 
pharmacokinetic parameters of A, Ka, IQ and apparent volume of distribution (Vd) 
and the non-compartmental model pharmacokinetic parameters of area under the 
curve (AUC), area under the moment curve (AUMC), mean residence time (MRT) 
and body clearance (CL) (Baggot, 1977; Gibaldi et al., 1988; Rowland et al., 1989; 
Wagner, 1979; Dunne et al., 1989; Wagner, 1976; Yamaoka, 1978; Vancutsen et al., 
1990; Hadi et al., 1994) were determined by RSTRIP computer software. 44 
3.4. RESULTS 
The average gentamicin plasma concentrations versus time profile of 
gentamicin sulfate salt with standard deviations at each sampling time of all four 
doses are shown in table 3.1. Mean values and standard deviations of the 
pharmacokinetic parameters were computed and are shown in table 3.2. The data 
of the six llamas was best fit to a biexponential function : 
Cp = Al e"  A2 e-)'2t  Eq. 3.2 
describing the declining gentamicin plasma concentrations as a function of time. 
The Cp is the gentamicin plasma concentration, X1 and X2 are distribution and 
elimination rate constants respectively and t is the time. 
The plasma concentration time curves of gentamicin after multiple dosing 
by IV bolus administration for days 1 through 4 are shown in figure 3.2, 3.3, 3.4 
and figure 3.5 respectively. The combined concentration time curve of the 
gentamicin plasma concentrations for all four doses is shown in figure 3.6. 
Figure 3.7 shows a comparison of the gentamicin plasma concentrations vs time 
after the first and the fourth IV bolus dose. 
Pharmacokinetics of gentamicin after the first IV bolus administration in all 
llamas fitted (correlation coefficient > 0.99) a two compartmental model with  Xi 
of 3.21 ± 1.12 hours', X2 of 0.31 ± 0.02 hours -1 and Kei of 0.71 ± 0.19 hours-1. 
The elimination half-life (t112) and the mean residence time were 2.27 ± 0.13 hours 
and 3.15 ± 0.15 hours respectively. The apparent volume of distribution at steady 
state and the body clearance were 0.39 ± 0.081/kg and 0.12 ± 0.02 l/kg/h 
respectively. 45 
The elimination half-life (t112) and the mean residence time of gentamicin 
calculated from the data of the fourth dose were 2.45 ± 0.19 hours and 3.42 ± 0.12 
hours respectively. The apparent volume of distribution at the steady state and the 
body clearance of the fourth dose were 0.36 ± 0.091/kg and 0.10 ± 0.09 l/kg/h 
respectively. 
Amikacin plasma concentrations, their means and standard deviations at each 
sampling time after intravenous (IV) bolus administration are shown in table 3.3. 
Mean values and standard deviations of the pharmacokinetic parameters were 
computed and are shown in table 3.4. The best fit for those data of six llamas was 
a biexponential function : 
Cp = Al et + A2 e-X2t  Eq. 3.3 
to describe the declining amikacin plasma concentrations as a function of time. The 
Cp is the amikacin plasma concentration, Xi and X2 are distribution and elimination 
rate constants respectively and t is the time. 
Mean curve of the amikacin plasma concentrations vs times after IV bolus 
administration is shown in figure 3.8. 
Pharmacokinetics of amikacin after the IV bolus administration in all llamas 
fitted (correlation coefficient > 0.99) a two compartmental model with Xi of 2.99 ± 
2.64 hours-', X2 of 0.25 ± 0.02 hours-1 and Kei of 0.71±0.13 hours-1. The elimination
 
half-life (t112) and the mean residence time were 2.77 ± 0.18 hours (h)
 
and 3.85 ± 0.17 hours respectively. The apparent volume of distribution at the steady
 
state and the body clearance were 0.33±0.04 1/kg and 0.08±0.01 1/kg/h respectively.
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Table 3.1  Gentamicin Plasma Concentrations vs Times after Four Intravenous 
Administrations ( 3.2 mg/kg over 1-2 min.) in Llamas 
Time  First Dose Drug Plasma Concentrations (14/m1) 
(hours) Llamal Llama2  Llama3  Llama4  Llama5 Llama6  Mean  SD 
0.25  8.50  10.89  10.55  8.31  7.15  8.67  9.01  1.43 
0.5  6.82  8.02  9.45  6.99  5.52  7.43  7.37  1.31 
1  5.26  5.85  8.87  5.26  4.40  6.02  5.94  1.54 
2  4.07  4.13  6.03  4.10  3.07  4.25  4.27  0.96 
4  2.00  2.06  4.33  2.07  1.96  2.45  2.48  0.92 
6  1.10  1.10  1.45  1.16  0.95  1.20  1.16  0.17 
8  0.61  0.62  0.81  0.61  0.59  0.53  0.63  0.09 
12  0.26  0.28  0.56  0.26  0.22  0.21  0.30  0.13 
24  ND  ND  ND  ND  ND  ND 
Time  Second Dose Drug Plasma Concentrations (4/m1) 
(hours) Llamal  Llama2  Llama3  Llama4  Llama5  Llama6  Mean  SD 
0.5  7.37  9.30  10.24  7.60  6.13  7.75  8.06  1.47 
1  5.58  7.70  8.52  6.13  4.45  5.45  6.30  1.52 
4  2.58  4.33  4.43  3.22  2.26  2.77  3.27  0.92 
8  0.63  1.00  0.79  0.69  0.54  0.71  0.73  0.16 
12  0.27  0.35  0.36  0.31  0.29  0.26  0.31  0.04 
24  ND  ND  ND  ND  ND  ND 47 
Table 3.1. (continued) 
Time  Third Dose Drug Plasma Concentrations (1.1g/m1) 
(hours) Llama1  Llama2  Llama3  Llama4  Llama5  Llama6  Mean  SD 
0.5  7.45  9.36  10.33  7.70  6.23  7.86  8.15  1.46 
1  5.78  8.04  8.81  6.18  4.47  5.50  6.46  1.64 
4  2.36  4.13  4.46  2.92  2.27  2.82  3.16  0.92 
8  0.63  0.97  1.00  0.66  0.53  0.71  0.75  0.19 
12  0.26  0.33  0.35  0.31  0.29  0.26  0.30  0.04 
24  ND  ND  ND  ND  ND  ND 
Time  Fourth Dose Drug Plasma Concentrations (mg/m1) 
(hours) Llamal  Llama2 Llama3  Llama4  Llama5 Llama6  Mean  SD 
0.5  7.53  9.58  10.74  7.81  6.38  7.97  8.33  1.56 
1  5.78  8.22  8.91  6.17  4.52  5.52  6.52  1.69 
4  2.43  4.16  4.59  3.01  2.30  2.90  3.23  0.93 
8  0.62  0.96  1.00  0.66  0.52  0.69  0.74  0.04 
12  0.26  0.33  0.35  0.30  0.29  0.26  0.30  0.04 
24  ND  ND  ND  ND  ND  ND 48 
Table 3.2. Pharmacokinetic Parameters for Gentamicin after Four Intravenous 
Administrations (3.2 mg/kg over 1-2 min) in Llamas 
First Dose 
Parameter  Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
A2  p,g/m1  5.35  9.19  1.68  3.99  5.03  2.85  4.68  2.59 
µg/m1  7.09  7.40  12.66  7.05  5.52  8.26  8.00  2.45 
4.08  3.32  1.04  3.18  3.71  3.96  3.21  1.12 
X2  111  0.30  0.31  0.33  0.30  0.28  0.32  0.31  0.02 
Kei  h "1  0.64  0.52  0.82  0.71  0.54  1.02  0.71  0.19 
t u2c,  h  0.17  0.21  0.67  0.22  0.19  0.18  0.22  0.20 
ti/20  h  2.29  2.26  2.14  2.33  2.49  2.15  2.27  0.13 
AUC  lig.h/m1 24.74  26.86  37.39  24.97  21.22  26.32  26.91  5.50 
AUMC  lig.h2/m1 77.68  79.26  118.65  80.11  71.82  79.53  84.51  17.00 
MRT  h  3.14  2.95  3.17  3.21  3.39  3.02  3.14  0.15 
Cl  1/h/kg  0.13  0.12  0.09  0.13  0.15  0.12  0.12  0.02 
Vp  1 /kg  0.26  0.19  0.22  0.29  0.30  0.29  0.26  0.04 
Vass  1/kg  0.41  0.35  0.27  0.41  0.51  0.37  0.39  0.08 49 
Table 3.2 (continued) 
Second Dose 
Parameter Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
Al  µg/ml  7.94  10.91  11.76  8.60  6.33  8.20  8.96  2.01 
114  0.29  0.29  0.29  0.29  0.27  0.29  0.29  0.01 
tin  h  2.40  2.40  2.37  2.43  2.57  2.37  2.42  0.08 
AUC  p,g.h/m1 27.43  37.71  40.15  30.09  23.48  28.02  31.15  6.44 
AUMC  p,g.h2/m1 94.78  130.32  137.08  105.26  87.05  95.80  108.38  20.56 
MRT  h  3.46  3.46  3.42  3.50  3.71  3.42  3.49  0.11 
Cl  1/11/kg  0.12  0.08  0.08  0.11  0.14  0.11  0.10  0.02 
V  1/kg  0.40  0.29  0.27  0.37  0.51  0.39  0.37  0.08 
Third Dose 
Parameter Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
Al  µg/m1  7.95  10.85  12.13  8.55  6.41  8.30  9.03  2.08 
Kit  111  0.29  0.28  0.29  0.29  0.27  0.29  0.29  0.01 
tir2  h  2.40  2.48  2.36  2.41  2.55  2.36  2.43  0.07 
AUC  gg.h/m1 27.51  38.74  41.36  29.78  23.55  28.29  31.54  6.96 
AUMC  lig.h2/tn1 95.15  138.37  141.06  103.72  86.60  96.41  110.22  23.50 
MRT  h  3.46  3.57  3.41  3.48  3.68  3.41  3.50  0.11 
Cl  Uh/kg  0.12  0.08  0.08  0.11  0.14  0.11  0.10  0.02 
0.26  0.37  0.50  0.39  0.37  0.08 Vass  Ukg  0.40  0.30 50 
Table 3.2 (continued) 
Fourth Dose 
Parameter  Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
Al  pg/m1  8.11  11.40  12.64  8.68  6.53  8.41  9.29  2.27 
11-1  0.30  0.30  0.30  0.29  0.28  0.30  0.29  0.01 
tit2  h  2.35  2.33  2.82  2.39  2.53  2.35  2.45  0.19 
AUC  lig.h/rn1 27.49  38.24  41.64  29.92  23.77  28.47  31.59  6.86 
AUMC  1.1g.h2/m1 93.12  128.29  137.12  103.15  86.59  96.43  107.45  20.47 
MRT  h  3.39  3.36  3.29  3.45  3.64  3.39  3.40  0.12 
Cl  1/h/kg  0.12  0.08  0.08  0.11  0.13  0.11  0.10  0.02 
Vas  1/kg  0.39  0.28  0.25  0.37  0.49  0.38  0.36  0.09 51 
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Figure 3.2 Mean gentamicin plasma concentration time curve 
of the first IV dose of 3.2 mg/kg. 52 
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Figure 3.3 Mean gentamicin plasma concentration time curve 
of the second IV dose of 3.2 mg/kg. 
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Figure 3.4 Mean gentamicin plasma concentration time curve 
of the third IV dose of 3.2 mg/kg. 10 
54 
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Figure 3.5 Mean gentamicin plasma concentration time curve 
of the fourth IV dose of 3.2 mg/kg. 10 
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Figure 3.6 Mean gentamicin plasma concentration time curves 
of four IV doses of 3.2 mg/kg. 10 
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Figure 3.7 Mean gentamicin plasma concentration time curves of the first 
and fourth IV doses of 3.2 mg/kg. 57 
Table 3.3. Amikacin Plasma Concentrations vs Times after Intravenous 
Administration( 12 mg/kg/day over 1-2 min.) in Llamas 
Time  Drug Plasma Concentration (4/m1) 
(hours)  Llamal  Llama2  Llama3  Llama4 Llama5  Llama6  Mean  SD 
5  min  45.51  44.89  46.01  50.21  40.51  38.86  44.33  4.09 
15 min  40.25  39.99  40.85  44.56  34.02  33.98  38.94  4.17 
30 min  35.68  35.51  36.03  39.24  29.23  28.99  34.11  4.11 
1  h  30.01  29.89  31.12  33.28  26.32  25.01  29.27  3.08 
1.5 h  25.56  25.86  25.87  26.68  23.56  21.14  24.78  2.06 
2 h  21.23  20.88  21.91  21.89  20.20  17.20  20.52  1.83 
3  h  17.21  17.02  17.35  17.03  16.65  13.92  16.53  1.30 
4 h  13.05  12.98  13.52  13.99  11.89  9.56  12.50  1.60 
6 h  8.56  8.45  8.62  8.85  7.51  6.23  7.37  1.73 
8  h  4.12  4.03  4.23  4.88  4.01  3.58  4.14  0.42 
12 h  2.05  1.98  2.15  2.52  1.65  1.35  1.95  0.41 58 
Table 3.4 Pharmacokinetic Parameters for Amikacin after Intravenous 
Administration (12 mg/kg over 1-2 min.) in Llamas 
Parameter Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean SD 
A2  µg/ml  36.14  36.03  36.86  32.05  33.98  29.93  34.16  2.72 
Ai  14/m1  11.66  10.90  11.22  19.87  14.62  11.11  13.23  3.53 
2.14  1.98  2.04  1.14  8.32  2.29  2.99  2.64 
X2  0.25  0.25  0.25  0.22  0.26  0.27  0.25  0.02 
Kei  111  0.76  0.77  0.77  0.44  0.79  0.75  0.71  0.13 
t1/20  h  0.32  0.35  0.34  0.61  0.08  0.30  0.23  0.17 
tv2x2  h  2.74  2.72  2.75  3.14  2.71  2.61  2.77  0.18 
AUC  pg.h/m1  148.52  146.95  151.78  162.58  134.44  117.55  143.64 15.65 
AUMC  lig.h2/m1  568.95  558.02  583.23  673.03  578.38  426.53  564.69 79.27 
MRT  h  3.83  3.80  3.84  4.14  3.86  3.63  3.93  0.17 
Cl  1/11/kg  0.08  0.08  0.08  0.07  0.09  0.17  0.08  0.01 
Vc  1/kg  0.25  0.26  0.25  0.23  0.25  0.29  0.25  0.02 
Vass  I/kg  0.31  0.31  0.30  0.31  0.38  0.37  0.33  0.04 59 
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Figure 3.8 Mean amikacin plasma concentration time curve
 
after 12 mg/kg IV bolus administration in llamas
 60 
Amikacin plasma concentrations, their means and standard deviations, at 
each sampling time after intramuscular (IM) administration are shown in table 3.5. 
Mean values and standard deviations of the pharmacokinetic parameters were 
computed and are shown in table 3.6. The data of six llamas was best fit to a 
biexponential function : 
en) Cp = A ( &Qt. - Eq. 3.4 
to describe the amikacin plasma concentrations profile as a function of time. 
The Cp is the amikacin plasma concentration, ki or Ka and A,2 or Kei are absorption 
and elimination rate constants respectively and t is the time. The mean amikacin 
plasma concentrations vs time after intramuscular administration of each llama  are 
shown in figure 3.9. 
Pharmacokinetics of amikacin after intramuscular administration in all 
llamas fitted (correlation coefficient > 0.99) a biexponential equation,  one 
compartmental model with first order absorption having Ka of 3.75 ± 0.15 hours' 
and Kei of 0.27 ± 0.01 hours"'. The elimination half-life (t112) and the mean 
residence time were 2.60 ± 0.14 hours (h) and 4.02 ± 0.20 hours respectively. 
The calculated peak concentration (Cmax) and the time to reach peak concentration 
(tmax) were 29.15 ± 3.4114/m1 and 0.76 ± 0.03 hours respectively. The observed 
peak concentration (Cmax) and the time to reach peak concentration (tmax) were 
34.20 ± 5.07 tg/ml and 0.5 ± 0.0 hours respectively. The apparent volume of 
distribution and the body clearance were 0.34 ± 0.04 1/kg and 0.09 ± 0.01 1/kg,/h 
respectively. 
Figure 3.10 depicts a comparison the drug concentration time curves of 
three aminoglycosides, amikacin, gentamicin, and tobramycin (data taken from 
Christensen et al., 1996) given by IV administration. Figure 3.11 shows a 61 
comparison of three aminoglycosides plasma concentrations when the dose has 
been normalized to 4 mg/kg body weight. 
3.5. DISCUSSION AND CONCLUSION 
The disposition of gentamicin following IV bolus injection for four 
consecutive doses followed linear pharmacokinetics. The pharmacokinetic 
parameters, half-lives, AUC, CL, and Vdss calculated from the plasma concentration 
profiles of the four doses are not statistically significantly different ( p-value > 0.05). 
The mean plasma concentration versus time profiles of the first dose and the fourth 
dose(assumed to be at the steady state) were not statistically significantly different 
(p-value = 0.06). 
The elimination half-life (t1/20) of gentamicin in llamas was 2.27 ± 0.13 h, 
whereas half-lives of 1.84, 1.59(2-3), 0.96, 0.76, 4.33 and 1.73 h have been 
reported for cats, humans, goats, rabbits, buffalo calves, and goats (Jerigan et al., 
1988; Hadi, 1994; Winter, 1988; Garg et al., 1995; Ogden et al., 1995; Garg et al., 
1992; Ahmad et al., 1994). The elimination half-life of gentamicin given IV bolus 
administration in llamas has been reported as 3.03 and 2.70 h (Dowling et al., 1995; 
Lackey et al., 1996). The mean body clearance of gentamicin given by IV 
administration was 0.12 ± 0.02 l/h/kg, whereas the body clearance of 0.06  0.102, 
0.17, and 0.07 l/h/kg have been reported for llamas, goats, rabbits, and humans 
respectively (Lackey et al, 1996; Ahmad et al., 1994; Ogden et al.; Winter, 1988). 
The mean apparent volume of distribution (Vd) was 0.39 ± 0.08 1/kg, whereas the 
Vdss of 0.25, 0.24, 0.11, and 0.21 1/kg have been reported for llamas, goats, rabbits, 
and humans respectively (Lackey et al, 1996; Ahmad et al., 1994; Ogden et al.; Hadi, 
1994). The pharmacokinetics of gentamicin in llamas from this study has larger 62 
Table 3.5. Amikacin Plasma Concentrations vs Times after Intramuscular 
Administration( 12 mg/kg/day over 1-2 min.) in Llamas 
Time  Drug Plasma Concentration (4/m1) 
(hours)  Llamal  Llama2  Llama3 Llama4 Llama5  Llama6  Mean  SD 
5 min  7.58  6.32  8.02  9.01  7.58  6.52  7.05  0.99 
15 min  20.41  18.46  23.12  25.65  21.20  19.01  21.31  2.69 
30 min  34.85  28.52  38.51  41.45  32.32  29.58  34.20  5.07 
1 h  29.89  24.23  32.08  35.21  28.22  25.24  29.15  4.50 
1.5 h  24.25  23.01  26.54  27.02  24.88  21.25  24.49  2.17 
2 h  20.75  18.56  22.05  22.89  21.86  18.14  20.71  1.95 
3 h  17.11  16.02  18.25  18.11  17.01  13.09  16.60  1.90 
4 h  13.55  11.68  13.98  15.02  12.23  9.78  12.71  1.87 
6 h  9.01  7.24  9.12  7.99  7.99  6.01  7.89  1.16 
8 h  4.98  3.87  4.88  5.1  4.86  3.96  4.61  0.54 
12 h  3.01  1.85  2.54  2.45  1.87  2.04  2.29  0.46 63 
Table 3.6 Pharmacokinetic Parameters for Amikacin Intramuscular 
Administration (12 mg/kg over 1-2 min.) in Llamas 
Parameter  Units  Llama1 Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
A  µg/ml  37.30  34.23  41.75  44.94  38.46  33.79  38.41  4.33 
Kel  11-1  0.24  0.26  0.26  0.28  0.27  0.28  0.27  0.01 
Ka  111  3.82  3.50  3.77  3.95  3.67  3.78  3.75  0.15 
t1/2  h  2.84  2.63  2.63  2.47  2.60  2.46  2.60  0.14 
tmax  h  0.77  0.80  0.76  0.72  0.77  0.74  0.76  0.03 
Cmax  µg/ml  28.94  25.66  31.79  34.10  29.06  25.37  29.15  3.41 
AUC  gig.h/m1  143.03  120.27  147.07  148.75  134.03  110.81  133.99 15.47 
AUMC  pg.h2/m1 623.35  491.18  596.02  567.74  539.99  421.96  540.04 73.72 
MRT  h  4.36  4.08  4.05  3.82  4.03  3.81  4.03  0.20 
CL  1/kg/h  0.08  0.10  0.08  0.08  0.09  0.11  0.09  0.01 
Vc  1/kg  0.34  0.38  0.31  0.29  0.34  0.38  0.34  0.04 64 
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Figure 3.9. Mean amikacin plasma concentration time curve
 
after 12 mg/kg IM administration in llamas
 65 
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Figure 3.10. Plasma concentration time curves of amikacin, gentamicin and 
tobramycin given IV bolus injection to llamas 10 
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Figure 3.11. Plasma concentration time curves of amikacin, gentamicin 
and tobramycin given by IV bolus injection after normalization 
to the dose of 4 mg/kg body weight of llamas. 67 
amount of gentamicin distributed to the tissues with a larger apparent volume of 
distribution at the steady state and a faster clearance with shorter half-life than the 
values reported in Lackey's (1996) study. 
In human, peak plasma concentrations of 6 to 10 tg/ml and trough 
concentrations of less than 2 µg/ml for gentamicin have been traditional goals of 
therapy (Barclay et al., 1994). Calculated dosage to achieve an average steady 
state plasma concentration (Cgs ave) within the therapeutic range, i.e., 4-8 tg/ml, 
was recommended for many severe infections (Sande & Mandel, 1980). The usual 
dose in human, in the past, for gentamicin and tobramycin administration in human 
is in the range of 50 -120 mg, administered over 30-60 minutes, every eight hours. 
Aminoglycosides exhibit concentration-dependent killing and produce prolonged 
persistent effects. Optimal dosage regimens of these drugs should maximize plasma 
concentrations (Craig, 1995). Once-daily dosing regimens for aminoglycosides (Gilbert 
and Bennett, 1989; Nicolau et al., 1992; Prins et al., 1993) meet this goal and also 
appear to reduce drug-induced nephrotoxicity (Craig, 1995). 
The dosage regimens of gentamicin are 6.6 mg/kg of body weight/day or 
2.2 mg/kg, every 8 hours for horses (Godber, 1995) and 4 mg/kg once daily or 
1 mg/kg every 8 hours for humans. A dosage regimen in the llamas of 3.2 mg/kg 
body weight once daily or 0.8 mg/kg every 8 hours administered parenterally 
provided adequate therapy of a peak at the steady state 8.29 µg/ml and trough less 
than 2 gg/ml. A predicted dosage regimen in the llamas of 4 mg/kg body weight 
once daily or 1 mg/kg every 8 hours administered parentally should provide more 
practical therapy. A peak plasma concentration at steady state of 10 µg/ml, and 
trough less than 2 gg/m1 should be obtained from dosing 1 mg/kg every 8 hours. 
Nephrotoxicity in llamas has not been reported in the literature, although 
prolonged gentamicin administration by owners has been reported to produce 
renal failure (Christensen, 1996; Smith, personal communication). 68 
From the amikacin plasma concentration profile, no statistically significant 
differences (p > 0.05) were observed for any of the pharmacokinetic parameters 
between IM and IV administrations. The absorption rate constant of amikacin after 
single IM administration of 12 mg/kg was K. of 3.75 ± 0.15  and elimination 
rate constant (IQ) of 0.27 ± 0.01 WI, whereas after single IV bolus administration 
of amikacin at the same dose had a terminal elimination rate constant (X2) of 
0.25 ± 0.01 III. 
The mean elimination half-lives (tu2,2) of amikacin in llamas were 
2.77 ± 0.18 h and 2.60 ± 0.14 h after IV and IM administrations respectively, 
whereas half-lives of 1.44, 2-3 h have been reported for chickens and humans after 
IV adminstration (Gammal, 1992; Winter, 1988). The mean body clearance of 
amikacin were 0.08 ± 0.01 and 0.09 ± 0.01 l/h/kg after IV and IM administrations, 
whereas the body clearance of 0.11, and 0.07 l/h/kg have been reported for 
chickens, and humans respectively ( Gammal, 1992; Winter, 1988). The mean 
apparent volume of distribution (Vd..) was 0.33 ± 0.04 and 0.34 ± 0.04 1/kg after IV 
and IM administrations respectively, whereas the Vdss of 0.19, and 0.21 1/kg have 
been reported for chicken, and humans respectively (Gammal, 1992; Hadi, 1994). 
In human, peak plasma concentrations of 20 to 30 p.g/m1 and trough 
concentrations of less than 10 pg/m1 for amikacin have been traditional goals of 
therapy (Winter, 1988). The usual dose, in the past, for amikacin is 200-500 mg 
administered over 30-60 minutes, every eight hours (Winter, 1988). 
A dosage regimen in the llamas of 12 mg/kg body weight once daily or 
4 mg/kg every 8 hours administered intravenously or intramuscularly should provide 
adequate therapy. A peak at the steady state 35 µg/m1 and trough less than 
10 µg/m1 should occur with dosing 4 mg/kg every 8 hours. 69 
The clearance, volume of distribution, and half-life of all aminoglycosides 
are similar in human (Winter, 1988; Simon et al.; Prins, et al., 1993). However, 
Zaske et al. (1991) showed that a wide interpatient variation in the kinetic 
parameters of the aminoglycosides in patients The half-life ranged from 0.7-14.4 h 
in 74 patients who had normal serum creatinine levels and from 0.7 to 7.2 h in 37 
patients who had normal creatinine clearance. From the data collected on three 
aminoglycosides in llamas (tobramycin, gentamicin and amikacin), it is apparent that 
their disposition and elimination is similar. 70 
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CHAPTER 4 
PHARMACOKINETICS OF OMEPRAZOLE AFTER IM
 
ADMINISTRATION IN LLAMAS
 
4.1. ABSTRACT 
The pharmacokinetics of omeprazole following intramuscular and rectal 
administration in llamas at a dose of 0.8 mg/kg body weight was investigated. 
Absorption from the site of injection was rapid with an absorption rate constant(Ka ) 
of 100 ± 0.00 hours-1. Elimination appeared to follow first order with a rate 
constant(Kel ) of 0.68 ± 0.04 hours' (h"1), yielding an elimination half-life (t112) of 
1.02 ± 0.07 h, a mean residence time of 1.49 ± 0.01 h, apparent volume of 
distribution of 1.54 ± 0.101/kg, and body clearance of 1.05 ± 0.13 1/kg/h.  The 
calculated peak concentration (Cmax) and the to time reach peak concentration (tmax) 
were 500.54 ± 31.14 ng/ml and 0.05 ± 0.0 hours respectively. The observed peak 
concentration (Cmax) and the time reached peak concentration (tmax) were 567.39 ± 
109.76 ng/ml and 0.083 ± 0.0 hours respectively. Plasma concentrations of 
omeprazole following the rectal administration were erradict and below therapeutic 
concentrations. 
Intramuscular administration of omeprazole was made available by 
developing a suitable formulation of omeprazole from the enteric coated granules 
by breaking them in a solution of bicarbonate then dissolving the omeprazole with 
propylene glycol. The omeprazole formulation was stable for three weeks at room 
temperature, 4°C, and -10°C. Rectal administration of the same omeprazole 
formulation as the IM administration provided minimal absorption of omeprazole 
with the plasma concentrations being less than 1 ng/ml 10 h post-administration. 75 
A dosage regimen of 0.8 mg/kg body weight/day of omeprazole IM for 
llamas provides plasma drug concentrations sufficient to significantly reduce acid 
production in the third stomach compartment. 
4.2. INTRODUCTION 
Gastric ulcer or perforating ulcer of the third compartment stomach in llama 
has been identified lately as a significant problem (Smith, 1994) and a contributory 
factor in the death of greater than 20 % of 87 cases handled by the OSU Diagnostic 
Lab. Gastroduodenal ulceration (peptic ulcer disease) is generally caused by 
intraluminal acid breaking down the barrier that normally prevents irritation, and 
autodigestion of the mucosa. The presence or absence of gastroduodenal ulceration 
depends upon a balance between mucosal damaging factors and mucosal protective 
factors (Wilson, 1990; Berardi et al., 1993). 
Gastrointestinal tract of herbivorous species (horses and ruminant animals) 
differs markedly from that of carnivores in anatomical arrangement. The horse, like 
the human, dog, and cat is monogastric. The ruminants (cow, sheep, goat etc. ) has 
a four-compartment stomach (rumen, reticulum, omasum, and abomasum), while 
the camelid (llama, alpaca, dromedary etc.) have a three compartment stomach. Not 
only is the anatomical arrangement of the digestive system of llamas different, but 
also its physiology and anatomy of epithelium cells (Smith et al., 1994; Baggot, 
1992). For llama, only the last one-fifth of the third comparment has epithelium 
designed to secrete acid and digestive enzymes, thus functioning as the stomach in 
the human and abomasum in the ruminant (Smith et al., 1994). Unlike the cow or 
goat, bacteria and protozoa in the forestomach of llama have digestive enzymes 
neccessary to break apart the plant material (Smith et al., 1994). This enzymatic 
metabolism might involve in some oral drug metabolism in the forestomach. 
For unknown reasons, some llamas produce either an excess of acid and 
digestive enzymes and/or have a breakdown of the protective lining covering this 76 
area. The net result is the development of an ulcer that may erode and damage the 
surface of the third compartment or in time erode all the way through the wall of 
the stomach compartment. Since the third compartment contents contain 
tremendous numbers of bacteria, perforations of the compartment result in bacterial 
contamination of the abdomen (peritoneal cavity). The resulting infections 
(peritonitis) can rapidly fill the the abdomen with combination of bacteria and pus. 
In some animals, the bacteria enter the systemic circulation and being carried by the 
blood are transported to the lungs where they result in severe pneumonia and 
death(Smith et al., 1994). 
Treatment of gastroduodenal ulcer in the past has been best achieved by 
reducing gastric acid secretion in llama as Helicobacter pylori has been to date not 
been isolated from the gastrointestinal tract of llamas with ulceration. Several drugs 
are employed to reduce acid secretion but drugs of the proton pump inhibitor's class, 
i.e. omeprazole, theoretically would be more effective. Other ruminants do not have 
H2 receptors and misoprostol is highly likely to be ineffective orally and toxic 
parenterally. 
Omeprazole has undergone extensive research and development in Europe 
by Astra Pharmaceuticals. More recently, it has been launched in the United States 
under license by Merck, Sharp & Dohme (West Point, Pennsylvania). In the United 
States, its approved indications are the short term treatment of duodenal ulcer, 
severe or refractory gastroesophageal reflux disease (GERD), and Zollinger-Ellison 
syndrome, and other hypersecretory states. 
Omeprazole, a substituted benzimidazole, is a specific and noncompetitive 
inhibitor of the enzyme fr/K+-ATPase, known as the gastric proton pump. It 
produces a profound and prolonged suppression of gastric acid secretion. Its 
potency in reducing acid secretion provides a more effective treatment for acid-
related disease in the upper gastrointestinal tract (Holt & Howden, 1991). 77 
The enzyme frIc-ATPase, located in the secretory canaliculi of parietal 
cells, actively secretes hydrogen ions in exchange for potassium ions. During 
parietal cell activation, intracytoplasmic vesicles containing H+/Ic-ATPase fuse 
with the apical membrane and its secretory canaliculi, exposing the  enzyme to the 
gastric lumen (Saccomani et al., 1979; Smolka et al., 1983; Helander et al., 1985). 
Omeprazole is a lipophilic weak base with an approximate pKa of 4. In 
mice, omeprazole is widely distributed within 5 min of intravenous administration, 
however, 16 hours later, it is virtually confined to parietal cells within the gastric 
mucosa (Helander et al, 1985). 
In the presence of acid within the secretory canaliculi of the parietal cell, 
omeprazole becomes protonated and, therefore, charged. In this form, it is unable 
to diffuse back across the cell membrane and so becomes localized in the acidic 
space of the secretory canaliculi. Here, omeprazole is converted to its active form, 
a sulfenamide and reacts irreversibly with a sulfhydryl group associated with gastric 
H±/KtATPase (Clissold et al., 1986). 
Inhibition of H+/K+-ATPase by omeprazole blocks the final common 
pathway for gastric acid secretion (Wallmark, 1986). This site of drug action 
contrasts with other available antisecretory agents including H2-receptor antagonists 
and anticholinergics, which act at receptors on the basolateral aspect of parietal cell 
(Berglindh & Sachs, 1985). Omeprazole blocks the response of H+/K+-ATPase to 
extracellular stimuli as well as to intracellular cyclic adenosine monophosphate 
(cAMP) which is a second messenger in the parietal cell (Wallmark et al., 1985). 
Omeprazole is unstable in conditions of low pH and so must be protected 
from the gastric acid when given orally. It is therefore administered as capsules 
containing enteric-coated granules of the drug. In human, absorption commences 
in the duodenum and peak plasma concentrations are achieved between 2 and 5 
hours (Regardh et al., 1985). However the absorption of omeprazole from the GI 78 
tract is highly formulation dependent (Clissold et al., 1986). Omeprazole has a 
plasma half-life of around 1 hour (Wallmark & Lindberg, 1987). Its pharmacological 
effect is, however, much more prolonged and so a once daily dosing regimen is 
employed. The degree of absorption of omeprazole increases during the first few 
days of treatment (Howden et al., 1984). The most likely explanation for this is that 
omeprazole progressively suppresses acid secretion over the first few days. 
Therefore, as less acid is present in the stomach as further doses of omeprazole are 
taken, less omeprazole degrades and more is absorbed. Food may slow the rate of 
omeprazole absorption without reducing the total amount absorbed (Rohss et al., 
1986). 
Omeprazole is about 95% protein-bound, mainly to albumin and al-acid 
glycoprotein (Regardh et al., 1985). It undergoes extensive metabolism by the liver. 
Its metabobolites : a sulfide, a sulfone and two hydroxyomeprazole, are mainly 
excreted in the urine, but around 20% is recovered in feces from biliary secretion 
(Regardh et al., 1985). 
Like other gastric antisecretory agents such as cimetidine, intragastric 
concentrations, bacteria, nitrite, N-nitroso compounds are temporarily increased 
during the treatment with omeprazole (Sharma et al., 1984; Ruddell et al., 1980). 
Omeprazole has no effect on the handling of acid or electrolytes by the kidneys 
(Howden & Reid, 1984). It only slightly reduces pepsinogen secretion (Lind et al., 
1983), but peptic activity is markedly reduced by omeprazole because pepsinogen 
is largely biologically inactive at the levels of pH that omeprazole produces. 
Secretion of intrinsic factor by parietal cells is unaffected by omeprazole (Kittang 
et al., 1985). Omeprazole has been shown not to affect gastric emptying, 
esophageal peristalsis, or lower esophageal sphincter pressure (Horowitz et al., 
1984). 
Comparative trials of omeprazole with ranitidine (Walan et al., 1989) or 
cimetidine in human (Bate et al., 1989) have shown higher healing rates of gastric 79 
ulcer than omeprazole. Omeprazole has been found to be highly effective in healing 
of severe or refractory peptic ulcers that are genuinely refractory to H2- receptor 
antagonists (Bardhan, 1989), in healing of all grades of esophagitis and in supressing 
symptoms to a greater degree than the H2- receptor antagonists (Blum et al.,  1989). 
In clinical trials involving treatment of approximately 200 patients with Zollinger-
Ellison syndrome for up to five years, gastric acid secretion has been adequately 
controlled, and this has been associated with marked improvement in, or abolition 
of symptoms (Maton et al., 1989). The drug has been well tolerated, even in high 
doses, and no histological changes in the gastric mucosa have been observed. 
In a previous study, ranitidine was given 1.5 mg/kg intravenously. 
Ranitidine slightly reduced the gastric acid secretion in the third compartment 
stomach of llamas for one hour suggesting a limited presence of H2- histaminergic 
receptors (Limsakun, 1995). In the same study, omeprazole was administered at 
a dose of 0.4 mg/kg intravenously, which effectively suppressed the gastric acid 
secretion in the third compartment stomach of llamas for over 6 hours at plasma 
concentrations greater than 60 ng/ml. While the 0.4 mg/kg oral omeprazole dosage 
produced peak plasma concentrations of approximately 20 ng/ml, by 6 hours post-
administration, plasma drug concentrations had only declined to approximately 12 
ng/ml suggesting that higher oral omeprazole dosages might be effective. 
Alternative routes of administration for omeprazole, rectal or intramuscular 
injection are needed for llama as the drug is inactivated in the stomach of llamas as 
the drug is released from the granules after oral administration. An intramuscular 
injection dosage form of omeprazole should be formulated and its method of 
dissolving the enteric-coated granules into appropriate solvents be made available 
to practitioners. 
The overall objectives of this project were to investigate rectal and 
intramuscular injection of omeprazole (Prilosec ®) as alternative routes of 
administration of the therapeutic agent for the management of the third 80 
compartment ulcers, and to develop a parenteral formulation of omeprazole for 
easy intramuscular administration of omeprazole for veterinary practitioners. 
Omeprazole is currently only available as capsules of enteric coated beads. 
Breaking the beads and making a suitable parenteral formulation is essential. 
Assessment of tissue damage after IM injections is vital to assure no harmful effects 
occur. Creatine kinase is the most accepted specific marker of tissue damage 
available for clinical use. It can be measured readily to monitor tissue damage of 
parenteral injections. It is used in this study to indicate if any damage occured after 
the IM omeprazole injection. 
4.3. MATERIALS AND METHODS 
4.3.1. Materials and Reagents : 
Omeprazole was obtained from Astra (Sweden). Phenacetin was obtained 
from Sigma Chemical Co. (St. Louis, MO). Acetonitrile (HPLC grade), absolute 
ethanol, methylene chloride (analytical grade), phosphoric acid, sodium chloride, 
sodium carbonate, sodium hydroxide, and potassium phosphate, monobasic were 
obtained from Aldrich Chemical (Milwaukee, WI), and polypropylene centrifuge 
tubes, 15-m1 capacity were obtained from J.T. Baker Chemical Co. (Phillipsburg, 
NJ). 
Stock omeprazole solution, 0.1 mg/ml, was prepared by dissolving 10 mg 
of omeprazole in 4 ml of absolute ethanol and diluting to 100 ml with carbonate 
buffer. Carbonate buffer, 50 mM, pH 9.3, was prepared by dissolving 0.53 g of 
sodium carbonate with 100 ml of distilled water. The pH was titrated with 
hydrochloric acid. 
Internal standard solution, 100 ig/ml, was prepared by dissolving 25 mg of 
phenacetin in 2 ml of absolute ethanol and diluting the volume to 25 ml with distilled 
water. Ten ml of this solution was further diluted to 100 ml with distilled water. 81 
Phosphate buffer, 0.05 M, pH 8, was prepared by dissolving 0.68 g of 
potassium phosphate, monobasic with 100 ml of distilled water and adjusting the 
pH with 3 M sodium hydroxide. 
Mobile phase consisted of 300 ml of acetonitrile and 700 ml of 5 mM 
phosphate buffer (0.68 g of potassium phosphate, monobasic per liter of distilled 
water). The mobile phase was titrated pH to 7.5 with 3-M sodium hydroxide, 
filtered through 0.47 µm filter, degassed under vacuum with sonication for 15 
minutes. 
A parenteral suspension of omeprazole using capsules, Prilosec® (MSD), 
containing enteric-coated granules, was formulated. Sufficient granules were used 
to provide a dose of 0.8 mg/kg body weight/day. The granules were disintegrated 
by vigorous vortex mixing in 1 ml of sodium bicarbonate solution for injection. 
It is essential all granules be totally broken down and uniformly dispersed in this 
step. Then, seven ml of propylene glycol was added and vortex mixed. Finally, 
eight ml of normal saline were added and vortex mixed. The omeprazole suspension 
must be left for at least 30 minutes before use. 
Stability tests of the formulation was performed at room temperature, 5°C, 
and -10°C. 
4.3.2. Animals : 
Four sexually mature healthy llamas (2 males and 2 females) and 2 sexually 
mature healthy alpacas (males) from the Oregon State University Camelid research 
herd, weighing between 150 and 185 kg for llamas, and between 58 and 64 kg for 
alpacas were used. All animals receive a routine health exam and are vaccinated and 
dewormed three times a year. No treatments were performed within two weeks 
before the study's initiation. 82 
4.3.3. Sampling Protocol : 
Twenty four hours before starting the study, an indwelling catheter was 
placed in the jugular vein and fitted with a catheter extension. A local lidocaine 
block was used to minimize the discomfort associated with the catheter placement. 
Feed and water were available ad libitum. The catheter was flushed once daily with 
10 ml of heparinized saline solution on non-sample days. Omeprazole was given as 
an intramuscular injection (IM) into the semimembranosus hind muscle of the llamas 
and as a rectal administration with a 72 hour wash out period between dosages. 
A 0.8 mg/kg body weight/day dose was given in random order to the llamas. 
Administration of IM or rectal omeprazole took 2-5 minutes to perform. Blood 
samples were collected via the catheter immediately before drug administration 
and 5 min,15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, and 10 h after the 
intramuscular administration and 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h and 
10 h after the rectal administration. The blood was transfered to evacuated tubes 
containing EDTA, and mixed thoroughly. After a blood sample was collected, the 
catheter was flushed with 10 ml of heparinized saline solution. Following collection, 
the blood sample was centrifuged, the plasma was decanted and frozen at -20°C 
until assayed. 
4.3.4. HPLC Assay : 
The HPLC system consisted of an HPLC pump (Model M-600 A; Waters 
Associates, Inc., Milford, MA), a WISP autosampler (Model 710 B, Waters 
Associates, Inc.), a variable wavelength detector (Model SP8773 XR, Spectra 
Physics Inc.,), and a recorder (Linear Inc.) The drug was eluted on a Microsorb-
MV C18 column (Rainin Instrument Co.) with a flow rate of 1.2 ml/min, detected at 
wavelength of 300 nm and sensitivity at 0.05 absorbance units, and recorded at 
chart speed of 10 cm/h from the received signal of the detector at a 5 mV scale. 83 
The assay method of omeprazole was modified from the method of 
Lagerstrom and Persson (1984). 0.3 ml of carbonate buffer (0.05 M, pH 9.3), 3 ml 
of omeprazole plasma samples, 0.1 ml of phenacetin solution (100  tg/ml), and 
0.5 ml of phosphate buffer (0.05 M, pH 8) were added into 15-nil polypropylene 
centrifuge tubes and vortex mixed. 0.25 g of sodium chloride granules were added 
and vortex mixed to dissolve the granules, and then 5 ml of methylene chloride was 
added. The tubes were capped turned up-side down gently once and uncapped to 
release internal pressure. The pressure releasing process was repeated 2-3  times. 
The extraction of omeprazole was performed by vigorous vortex mixing for 5 min, 
and centrifuging at 10,000xg for 15 min. The upper layer was discarded, the lower 
methylene chloride layer was decanted into a set of appropriately labeled glass tubes. 
The methylene chloride layer was evaporated to dryness. The residue was 
reconstituted with 200 Ill of the mobile phase, vortex mixed and 100 l.t1 of this 
solution was injected into the HPLC system. 
A standard curve was created by making serial dilutions of the omeprazole 
stock solution creating concentrations of 0, 0.5, 1, 2, 3, 4, and 5 µg/ml in carbonate 
buffer. Into 3 ml of blank(drug free) llama plasma, 0.3 ml of each omeprazole 
solution was placed into 15-nil polypropylene centrifuge tubes, and vortex mixed. 
Standard samples were prepared and extracted as described for the unknown 
samples. Three standard curves were run over a three week period. Peaks of 
phenacetin and omeprazole were clearly separated and eluted within 20 min. 
Mean retention times for phenacetin, the internal standard and omeprazole were 
11 and 18 min respectively. 
Assay method for the stability test of the omeprazole formulation was 
created by making triple serial dilutions of the formulation with the carbonate 
buffer until the concentration was about 3 - 4 tg/ml. Standard omeprazole 84 
solutions of concentrations of 0, 1, 2, 3, 4, and 5 µg/ml were prepared. 100 tl of 
mixture(' :1) of the omeprazole solutions and the internal standard solution was 
injected into the HPLC system using a flow rate of 1.4 ml/min and recorder 
sensitivity of 10 mV. Phaenacetin and omeprazole were clearly separated having 
mean retention times of 6 and 11 min respectively. 
Least sum of squares regression of peak height ratios of omeprazole to 
internal standard versus the concentrations of the omeprazole standard solutions 
provided the standard curve. The sample concentrations were calculated by using 
the regression results of the standard curves. 
4.3.5. Pharmacokinetic Analysis : 
Plasma concentrations vs. time data were analyzed using RSTRIP 
Computer Software (1992) to fit the data. The data was weighted 1/(plasma 
concentration) to get a best fit rather than equally weighted plasma concentrations 
or weighted 1/(plasma concentration)2 (Wagner, 1975). 
The plasma concentrations as a function of time after intramuscular 
administration in each llama were fitted to polyexponential equations. Nonlinear 
least squares fit of each data set was performed to a general equation : 
Cp =  e "kit  Eq. 4.1 
Where Cp is the omeprazole plasma concentration, Xi are the exponents, A, are the 
preexponential coefficients and t is time was obtained by using the number of terms 
required for each subject. 
Both the compartmental model dependent pharmacokinetic parameters of 
A, Ka, Key  ,  half-live (t112) and apparent volume of distribution (Vd) and the non-
compartmental model pharmacokinetic parameters of area under the curve (AUC), 85 
area under the moment curve (AUMC), mean residence time (MRT) and body 
clearance (CL) (Baggot, 1977; Gibaldi et al., 1988; Rowland et al., 1989; Wagner, 
1979; Dunne et al., 1989; Wagner, 1976; Yamaoka, 1978; Vancutsen et al., 1990; 
Hadi et al., 1994) were determined by RSTRIP computer software. 
4.4. RESULTS 
Omeprazole plasma concentrations, their means and standard deviations at 
each sampling time after intramuscular (IM) administration are shown in table 4.1. 
The omeprazole plasma concentrations after the rectal administration were too 
low to detect by the described assay method. Mean and standard deviation 
values of the pharmacokinetic parameters fitted by RSTRIP with weighted of 
1/plasma concentration and 1/(plasma concentration)2 are shown in table 4.2 and 
table 4.3 respectively. The data of six llamas was best fit to a biexponential 
function (correlation coefficient > 0.98): 
Cp = A( e-'2' -eit)  Eq. 4.2 
to describe omeprazole plasma concentrations as a function of time. The Cp is 
the omeprazole plasma concentration, XI or Ka and X2 or Kel are absorption and 
elimination rate constants respectively and t is the time. The profiles of the mean 
omeprazole plasma concentrations vs times after intramuscular administration for 
llamasfrom both fits are shown in figure 4.1. 86 
Table 4.1. Omeprazole Plasma Concentrations vs Times after Intramuscular 
Administration ( 0.8 mg/kg/day over 2-5 min.) in Llamas. 
Time  Drug Plasma Concentration (.4m1) 
(hours)  Llamal Llama2  Llama3  Llama4 Llama5  Llama6  Mean  SD 
5 min  552.10  522.66  460.13  500.73  501.32  507.39  33.72 
15 min  489.26  441.06  495.52  465.53  472.80  24.82 
30 min  423.56  391.68  335.21  374.05  428.41  402.01  392.49  34.55 
40 min  349.56  375.38  316.83  347.26  29.34 
1 h  245.00  246.66  191.96  194.57  261.35  205.05  224.10  30.34 
2 h  153.10  107.25  91.32  102.28  155.02  106.18  119.19  27.60 
3 h  66.58  66.78  50.25  53.45  69.01  58.77  60.81  7.82 
4 h  43.21  48.23  37.06  40.51  45.26  44.45  43.12  3.90 
5 h  29.14  29.68  19.14  24.24  32.48  26.95  26.94  4.72 
6 h  21.22  16.19  12.11  15.01  23.53  18.28  17.72  4.18 
8 h  14.78  7.20  4.20  8.44  16.22  11.11  10.32  4.61 
10 h  10.99  3.26  2.50  4.56  11.87  7.85  6.84  4.01 87 
Table 4.2. Pharmacokinetic Parameters for Omeprazole after Intramuscular 
Injection (0.8 mg/kg over 3-5 min) in Llamas 
Para- Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean SD 
meter 
A  ng/ml  553.44  532.21  466.26  511.42  547.16  528.78  523.21 31.57 
Ka  100.0  100.0  100.0  100.0  100.0  100.00  100.0  0.00 
IQ  111  0.64  0.66  0.72  0.73  0.62  0.71  0.68  0.04 
ti/2  h  1.08  1.04  0.97  0.95  1.12  0.98  1.02  0.07 
tmax  h  0.05  0.05  0.05  0.05  0.05  0.05  0.05  0.00 
Cmax  ng/ml  532.17  511.23  446.70  489.67  526.89  506.82  500.54 31.14 
AUC  ng.h/m1  853.06  795.25  645.51  696.17  881.89  741.35  768.87 91.45 
AUMC  ng.h2 /ml  1332.0  1204.2  906.57  961.60  1439.0  1054.2  1149.6 211.43 
MRT  h  1.56  1.51  1.40  1.38  1.63  1.42  1.49  0.10 
Vd  1/kg  1.45  1.51  1.73  1.58  1.47  1.52  1.54  0.10 
CL  l/kg/h  0.94  1.01  1.24  1.15  0.91  1.08  1.05  0.13 88 
Table 4.3. Pharmacokinetic parameter of omeprazole after IM administration 
at a dose of 0.8 mg/kg fitted by weighting 1/(plasma concentrations)^2 
Para- Units  Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
meter 
A  ng/ml  412.19  384.89  332.25  343.05  329.07  315.13 352.76  37.57 
Ka  h-1  100.00  100.00  100.00  100.00  100.00  100.00 100.00  0.00 
Kel  h-1  0.50  0.51  0.55  0.51  0.43  0.46  0.49  0.04 
Cmax  ng/ml  399.41  372.74  321.12  332.28  320.09  306.01 341.94  36.18 
tmax  h  0.05  0.05  0.05  0.05  0.05  0.05  0.05  0.00 
t1/2  h  1.39  1.36  1.27  1.37  1.62  1.51  1.41  0.13 
AUC  ng.h/ml  824.36  753.33  605.32  675.81  767.30  684.54 718.44 78.21 
AUMC  ngh2/m1  1665.2  1489.5  1114.9  1344.9  1804.5  1500.7 1486.6 241.4 
MRT  h  2.02  1.98  1.84  1.99  2.35  2.19  2.06  0.18 
Vd  1/kg  1.95  2.09  2.42  2.34  2.44  2.55  2.30  0.23 
CL  1/kg/m1  0.97  1.06  1.32  1.18  1.04  1.17  1.11  0.13 89 
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Figure 4.1 Mean omeprazole plasma concentration time curves after 
0.8 mg/kg IM administration in llamas fitted with RSTRIP and 
weighted with 1/plasma concentration and 1/(plasma concentration)2 90 
The disposition of omeprazole after intramuscular administration in llamas 
fitted by RSTRIP withweighted 1/plasma concentration revealed a first order 
absorption rate constant (Ka) of 100 ± 0.00 hours-1 (111) and an elimination rate 
constant (IQ) of 0.68 ± 0.04 hours-1(h-1). The elimination half-life (t1/2) and the 
mean residence time were 1.02 ± 0.07 hours (h) and 1.49 ± 0.01 hours 
respectively. The calculated peak plasma concentration (C.) and the to time 
reach peak concentration (t.) were 500.54 ± 31.14 ng/ml and 0.05 ± 0.0 hours 
respectively. The observed peak concentration (C.) and the to time reach peak 
concentration (tmax) were 567.39 ± 109.76 ng/ml and 0.083 ± 0.0 hours 
respectively. The apparent volume of distribution and the body clearance were 
1.54 ± 0.101/kg and 1.05 ± 0.13 l/kg/h respectively. 
However, the plasma concentration time prfilles of all six llamas should be 
fit to triexponential equations as shown in figure 4.2. All data were fitted again 
by WINNONLIN with a two compartment and first order input model weighted 
1/(plasma concentration)2. The pharmacokinetic parameters are shown in table 4.4 
and the mean plasma concentration with a predicted line are shown in figure 4.3. 
The stability test of the omeprazole formulation kept over a month at room 
temperature, 4°C, and -10°C showed that 69% ± 3.0%, 71% ± 1.65%, and 72 % 
± 1.17 percent of labeled amount of drug was present respectively. The percent 
labeled amount was assayed every week as shown in table 4.5. At room temperature, 
the color of omeprazole formulation changed from white to yellow within 2 days. 
Creatine kinase(CK) activity measured from OSU veterinary diagnostic 
laboratory at times 0, 1, 2, 3, 6, 24, 48, and 96 h postdose showed that the CK 
activity significantly increased in most llamas and reduced within 24 h as shown in 
table 4.6. Four sections of skeletal muscles from llamal and three sections from 
llama3 were examined. Lesions were confined to tissues of llamal. All lesions 91 
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Figure 4.2. Plasma concentrations of omeprazole in 6 llamas after 
1M adrninis',ration(0.8 mg/kg). 
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Table 4.4.  Pharnacokinetics parameters of omeprazole after IM administration at a 
dose of 0.8 mg/kg (Fitting by WINNOLIN computer software weighted 
1/(plasma concentration)2 
Para- Units Llamal Llama2 Llama3 Llama4 Llama5 Llama6 Mean  SD 
meter 
A  ng/ml  530.00  585.49  463.31  453.86  569.08  498.49  516.71  54.37 
A2  ng/ml  38.71  243.95  187.14  122.59  48.92  84.47  120.96  80.99 
Ka  h-1  190.38  16.43  20.04  36.67  16.92  33.24  52.28  68.20 
h-1  0.82  1.94  1.70  1.28  0.87  1.10  1.29  0.45 
X2  h-1  0.13  0.44  0.45  0.33  0.14  0.25  0.29  0.14 
K10  h-1  0.60  0.93  0.93  0.79  0.61  0.73  0.77  0.15 
K12  h-1  0.17  0.54  0.40  0.28  0.20  0.25  0.31  0.14 
K21  h-1  0.18  0.91  0.83  0.54  0.20  0.37  0.50  0.31 
ti/20  h  0.84  0.36  0.41  0.54  0.80  0.63  0.54  0.20 
tv2k2  h  5.41  1.59  1.53  2.08  4.87  2.82  2.39  1.69 
AUC  ng/ml.h  943.96  810.56  652.59  707.30  961.36  777.59  808.89  124.28 
Vd  L/kg  1.41  1.06  1.52  1.43  1.36  1.42  1.37  0.16 
CL  L/h/kg  0.85  0.99  1.23  1.13  0.83  1.03  0.99  0.16 
Tmax  h  0.03  0.16  0.15  0.10  0.19  0.11  0.12  0.06 
C.  ng/ml  553.80  596.83  501.53  503.31  505.19  508.66  528.22  39.01 93 
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Figure 4.3 Mean plasma concentrtaion of omeprazole in llamas after 
IM administration(0.8 mg/kg) fiited with WINNONLIN 
and weighted 1/(plasma concentration)2 94 
Table 4.5. Stability Test of Omeprazole Formulation 
Conditions 
% Labeled Amount 
Week()  Weekl  Week2 
Room Temperature 94.89±0.16 94.03±0.77 93.27±2.16 
Week3 
86.96±1.31 
Week4 
69.79±3.0 
(25 °C) 
4 °C  96.63±1.48 97.08±0.62  93.84±3.75  89.22±2.19  71. 86±0.65 
- 10 °C  96.54±1.03  96.50±1.35  93.81±2.71  89.84±2.14  72.36±1.17 
Table 4.6.  Creatine Kinase Activity after Omeprazole Intramuscular Administration 
(Normal range of CK = 25 - 200 IU/L) 
Time(h)  Llamal  Llama2  Llama3  Llama4  Llama5  Llama6  Mean SD 
0  15  15  16  33  25  11  19.2  8.2 
1  92  60  126  131  32  14  75.8  48.6 
2  168  106  193  233  49  16  127.5  5.0 
3  222  190  225  221  62  16  156.0  92.7 
6  315  252  311  107  111  14  185.0  124.9 
24  112  140  164  72  91  15  99.0  52.8 
48  46  45  31  29  34  17  33.7  10.8 
96  16  23  16  14  15  14  16.3  3.4 95 
showed similar changes. There was a central focal area of hemorrhage and 
necrosis which was surrounded by a large area of granulomatous inflammation. 
4.5. DISCUSSION AND CONCLUSION 
The omeprazole plasma concentrations after single IV bolus administration 
in llamas at the dose of 0.8 mg/kg body weight declined rapidly revealing a rapid 
distribution phase. The elimination half-life (t112) and the mean residence time were 
1.38 ± 0.26 hours (h) and 1.03 ± 0.18 hours respectively. The apparent volume of 
distribution and the body clearance were 0.36 ± 0.07 I/kg and 0.18 ± 0.05 l/kg/h 
respectively. The area under the curve was 4509.8 ± 970.2 ng.h/ml. Omeprazole 
showed dose-dependent pharmacokinetics from the dose of 0.2 to 0.8 mg/kg body 
weight of llamas (Limsakun, 1995) because of saturation of its metabolism. 
The pharmacokinetics of omeprazole after intramuscular administration in 
llamas at the dose of 0.8 mg/kg body weight fiited by RSTRIP with a weighting 
factor of 1/plasma concentration showed a very rapid absorption with a first order 
absorption rate constant (Ka ) of 100 ± 0.00 hours1 (14), an elimination rate 
constant  (Kei ) of 0.68 ± 0.04 hours' (h"'). A shorter elimination half-life (t112 of 
1.02 ± 0.07 h), a longer mean residence time (MRT of 1.49 ± 0.01 h), a larger 
apparent volume of distribution (1.54 ± 0.101/kg), a faster body clearance 
(1.05 ± 0.13 1/kg/h), and a smaller the area under the curve (768.87 ± 91.45 ng.h/m1), 
were obseved after IM injection compared to those from the IV administration. 
After IM administration over 3-5 minutes, the omeprazole was absorbed very 
quickly providing the calculated peak plasma concentration (Cmax) and the time 
reached peak concentration (tmax) of 500.54 ± 31.14 ng/ml and 0.05 ± 0.0 hours 
respectively. The observed peak plasma concentration (Cmax) and the time reached 
peak concentration (tmax) were 567.39 ± 109.76 ng/ml and 0.083 ± 0.0 hours 
respectively. In human, the tmax was highly formulation dependent. T. was less 96 
than 20 (12-17) minutes for solutions of omeprazole, about 30 minutes for 
uncoated omeprazole granules, and between 2 and 5 hours for enteric-coated 
granules of the omeprazole ( Clissold et al., 1986). 
The pharmacokinetic parameters of omeprazole fitted by WINONLIN 
with a weighting factor of 1/(plasma concentration)2 were the most appropriate 
parameters. They are shown in the table 4.4. 
Omeprazole, an acid labile drug, is widely available as an oral dosage form, 
capsules containing enteric coated granules of omeprazole. However, omeprazole, 
given 0.4 mg/kg orally, slightly reduced the gastric secretion in the third 
compartment stomach with the peak plasma concentration of 20 ng/ml(Limsakun, 
1995). After a preliminary study in 2 llamas, omeprazole given 0.8 mg/kg orally, 
had peak plasma concentrations less than 25 ng/ml which is less than the therapeutic 
concentration of 60 ng/ml. The omeprazole enteric coated granules breakdown 
in the llamas' GI tract prior to the third compartment stomach releasing 
omeprazole which is degraded in the third stomach before reaching the absorption 
site of the small intestine. 
Intramuscular administration provides an alternative route. By making a 
suitable formulation of omeprazole from the enteric coated granules for IM injection, 
the problems of instability and degradation in the upper gastrointestinal tract of 
llamas is avoided. The omeprazole parenteral formulation prepared and used in this 
study was stable for three weeks at room temperature, 4°C, and -10°C as shown in 
the table 3.3. 
The omeprazole formulation, omeprazole was dissolved in a cosolvent of 
90% propylene glycol before being diluted to 50% propylene glycol with normal 
saline for injection. The coating materials were suspended in the formulation. 97 
The muscle inflammation observed at the injection site might be caused by 
two possible reasons. First is the coating materials suspended in the formulation 
and second is the large volume of fluid injected (16 ml). The first reason can be 
remedied as the coating materials can be discarded from the formulation by 
centrifugation before drug administration. The supernatant containing the 
omeprazole should be administered in a future study and the omeprazole plasma 
concentrations and the CK activity should be remeasured to confirm this.  The 
volume of propylene glycol needs to be at least lml per 1 capsule of omeprazole 
after the granules are disintegrated in 1 ml of sodium bicarb to get maximum 
solubility of omeprazole. If a higher percentage of propylene glycol can be easily 
injected, the volume of sodium chloride can be reduced. 
Rectal administration of the same omeprazole formulation as the IM 
administration provided minimal absorption of omeprazole with plasma 
concentrations being less than 1 ng/ml 10 hours post-administration. However, 
rectal administration of omeprazole has been reported in human (Choi et al., 1996). 
With the appropriate suppository base, rectal administration might be an alternative 
route of administration of omeprazole in llamas. 
The dosage regimen of omeprazole for llamas at 0.8 mg/kg body weight 
a day given intramuscularly is appropriate to get the peak plasma concentration of 
550 ng/ml which is slightly greater than that of 460 ng/ml from the 0.2 mg/kg IV 
administration (unpublished data of Limsakun, 1995). However, a better 
formulation of omeprazole needs to be developed for IM administration. 98 
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CHAPTER 5 
CONCLUSION 
Ampicillin sodium given intramuscularly is an effective route of 
administration provided adequate therapy at a dose of 24 mg/kg body weight 
twice daily or 12 mg/kg every 6 hours. Llamas cannot absorb ampicillin from the 
injection site when the trihydrate form is given. A dosage regimen in llamas of 
4 mg/kg once a day or 1 mg/kg every 8 hours administered intravenously should 
provide adequate therapy and reduce incidence of toxicities. A dosage regimen in 
llamas of 12 mg/kg once daily or 4 mg/kg every 8 hours administered intravenously 
or intramuscularly provide adequate therapy. Intramuscular administration is an 
effective alternative route of administration for omeprazole to get therapeutic 
plasma concentrations at a dose of 0.8 mg/kg once daily whereas rectal 
administration has minimal absorption. 103 
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